2025-03-31-accounts

REGISTERED CHAIUTY NUMBER: 1159115 Report of the Tr￿stee5 and Fmnkncial Statements for the Year Ended 31 March 2025 for British Paediatrie Neurology Association

Britlsh Paediatrlc Neurology Assoclation Contents of the Financial Statements ror the Year Ended 31 March 2025 Page Report of the Trustees I to 29 Report ofthe Independent Auditor 30 to 32 Stslement of Financial Aetivities 33 10 34 Balance Sheet 35 Cash Flow Stalement 36 Notes to the Casb Flow Sthlement 37 Note5 to the Finaneial Statements 38 to 57

British Paedlatrl¢ Neurology Association Report of the Trustees for the Year Ended 31 March 2025 The trustees present their repoTt with the fjnancial statements of the chatity for the year ended 31 March 2025. The trnstees havc adDplLd the provisions of Accounting and Reporting by Charilies." Staternenl of Recomtnendcd Practice applicable to charilic8 preparing their accounts in accoidance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effcctive l January 2019). President's Report rhe BPNA has had another very produciive year and l aJn grateful to ihe secretariat, under the strong leadership of Philip Levine. and all our members and collaborators who have allowed the organisation to achieve this. We started the Y￿ with some fjnancial concern relating lo VAT as following two external VAT reviews. commissioned by the BPNA, it Wds concluded that we should have bcen VAT Icgistercd since 2018. The secretaridt have successfully recouped VAT from cligible companies meaning that thc fJnancia] implications were significantly reduced. Overall, the financial posiiion of the charily remain& healthy. though the trustecs conlinue to pay closc atiention to the mix of activities in order to ensure Ihat in trying to achicve its objeLtives il does nol Icad io deterioration in the financial stability of the charity or 51aff burn out. This report summarises the depth and breadth of our activities over the past year and I would like lo highlight JUSI a few of these: We had a strategy day and created a Vision and Mission and are developing the BPNA direction in the coming years which will include a review of how Trustees and Executive structured - We have started the scoping for a new website and plan to rebrand and redesign between 2025 and 2026 - The conlinuing growth in our membership, llow sitting at 732 members A very successful hybTid conferen¢e in Oxford attended by 861 Delegales from 55 drfferent Counties - Building on our PPI activities with involvemeTJt in short course writing and well received charity videos at the annual conference Launch of the PET Foundation course malerials, which have been designed by BPNA and ESNA foT ,gpecialist nurse or paediairicians with expertise in epilepsy to deliver face to lace small group taching in local non-health seitiug such as schools and nurseries Launch of French translation of PETI in Tunisia Publication of a paper demonstrating outcomes from PETI course including that 98% of PETI delegates change their clinical pEactice after attending the course Vcry succcssful Paediatric Neurology Grid round aP￿]nting I l traTDees in highly competilive inlcrviews ]ncaning that Tecruiiment has now stabilised Expansion of Professiona] Support aclivities io include new Grid Trainees Support Pmgram and training sessions for senior mentors Life does not get any easier in the NHS or academic institutions so I would again like to acknowledge the commitment and enthusiasrn of the Executive, Council. SIG leads and all volunteers and BPNA membcrs who find the time lo contribulc lo the BPNA and of course our amazing seCret￿latI We Rgreed Ihat thc Vision for the BPNA i.s To create a world where every child and young person wilh a neurological condition can access the c￿e and support they need to reach theiT full potential. and this report summaTises all the work we are doing together to realise this. Dr Ailsa McLellan Page I

British Paediatric Neurology Assoclatlon Report of the Tr￿lee5 for the Year Ended 31 March 2025 BPNA President (2024 - 2027) OBJECTtVES AND ACTIVITIES Objectives and aim5 Thc Brilish Paedialric Neurology Association (BPNA) is a charitable Ancorporaled organisation Tegislered with the Charity Comtnission for F.ngland and Walcs on 6 Novembcr 2014 with Ihc charity numbcr 1159115. The cbaTiiable objeclive.g are to promote ihe health wid well-being uf children with neurological disorders through.. The training and education of professionals working in the field of paediatric neurosciences. The prornolion of rescarch into the causes. effects and treatmcnts of neurological disorders affecting childicn aDd young pcople., The improvement of knowledge of professionals. Ihe public and patients and their families through scientifjc and educational meetings. and The provision of professional supporl to members to facilitate the delivery of the above objectives and work with health service planners and providers to achieve this aim. MaAn aetlvities undertsken in relatlOD lo the purpose Vision and Mission BPNA Vision: To create a world where every child and young person with a neumlogical condition Can access the care and support they need lo reach their full potential. BPNA Mission.. To work in partnership with oiher organisations in advancing the health and well-being of cbildren and young people with neurological conditions by- . Promoting equitable access to hIgh-q￿alItY healthcare and resources. Supporting healthcare professionals nationally and internationally through training and education lo improve clinical practice. Fostering research iniiiatives thar empower clinicians, patients. and families. . Ch￿nplonlng healthy brain development ihrough advocacy and collaboration. Please see full details of each activity provided in 'Aehievement and performan¢e'. Training thc next generation of paediatriL neurologists in the UK. Educaiing professionals in the UK and internationally in the diagnusis and managcment of.. Epilepsy, through provision of PAediaLric Epilepsy Training ￿ET) and Expert lo Expert.. Epilepsy COUTses: Headaches, Ihrough proviston of Children's Headache Training {CHaT) courses- Neonatal neurology. through provision of (NeoNATE) courses Abnormal muscle tone: through provision ol the Approaching Children's Tone (ACT) courses Acutc neurolngical disorder.s through thc newly dcvelopcd course AcutL Children with any type of neurological condition through its comprehensive online distance learning course Page 2

British Paediatric Neurology Association Report of the Truslees ror the Year Ended 31 March 2025 OBJECTIVES AND ACTIVITIES Improvement of knowledge of professlonals, Ihe public and patients through the annual scientific meeting held in Jalluary. Promotion of research through: British Pacdiatric Neurology Surveillance Unil (BPNSU)" 2nd PaediatriL Neurulogy Research Fellnwship. Provision of professional support through.. Mentoring: Te￿ qupporl" Special interest group.s Public benefit The trnslees have had regard lo Ihe ch￿IlY Commission's gu?danee on pub]ic benefit in considering activities during 2024-25. They soughi to meel the public benefil of promoting the health and wellbeing of children with neurological disorders in the UK and globally through the initiatives and projects listed in the section Main activities undertaken in relation to the purpose,. Gran¢n￿kIng During 2024-25, the charity provided £41.666 funding in Ihe final year of three for the third joint BPNA Aciion Medical Research fellowship. Volunleers BPNA faculiy in the UK and overseas directly contributed to rhe developrnent and delivery of courses and distance le8Thing. They also contribute their expertise in ihe other areas of the BPNA including Professional Support and Research as Chair, Council and Committee members. You can define ail these people as volunteers who give their time to the BPNA as a chatity. Their contribution is significant lo the ongoing activaies of the BPNA and the trustees wholeheartedly appreciate this commiiment and thank them. Fundraising BPNA raises funds through applying for gr2nis and sponsorship from organisaiions that have the same interests. The chatily has used its own staff for fundraising and not any external fundraisers. Tlie charity is noi a member of any voluntary scheme for regularing I'undraising. All fundraising activities monitored by the Executive DireLlor and the charily has noi received any complaints regarding I￿ fundraising aclivities. The charity doesnl come inio contact with vulnerable people as it is noi involved with Street or door to door fundraising. ACHIEVEMENTS AND PF.RFORMANCE Charilable aetivities l. Training - l. Paediatric Neurolo v Sub_s Liali Trainin Thc BPNA continues to have responsibility for training paediatric neurologists in the UK with BPNA meTnbers serving on the Royal Collegc of Paediatrfftcs and Child Healih (RCPC.H) College Specialist Advisory Comtnitiee (CSACI for neurology. The committee is Chaired by Ihe BPNA President aTJd includes the BPNA National Training Advisor. The GMC and RCPCH Shape of Training (SOT) plans on paediatric neurology training commenced in Augusi 2n23. Moving forward, neurology GRtD trainees will commence GRID training ai ST5 (lather than ST6 level as previous). It has been agreed thal neurology GRID trainees will still have up to 3.5 years lo meet learning objectives. Page 3

British Paedlatric Neurology Assoclation Repor¢ of the Trustees for the Year Ended 11 March 2025 1.2. New CUTTI￿]UM Trainees and their educational supervisors becoming more familiar with ihe Level 3 neurology 'Progress' syllabus, which was launched in August 2018. The BPNA Tratning Guide to Neurology, published on the RCPCH webslte. continues to pmvide more specific and siructured infornialion on how to achieve the learning objectives and capabilities for Level 3 neuTology (GRID) training. The CSAC has developed an Annual Progression Form which iucorporaies the curriculum and trainees have provided POSAiive feedback regarding ihis. 1.3. A inlment of new 'd trainees For the 2025 paediairic neurology GIUD training programme, there were I I GRID training schemes available. Over thirty applications were received, and 22 trainees were shortlisted for interview. 16 ¢andida*s were deemed appointable, and I l trainees accepted a GRID position. Overall, this is a huge increase in numb¢r of trainees applying to the GRID scheme. Ii is anticipated that there will be less GRID posts advertised in 202&2027 as pIeviously unfilled vacancies over the years have now been filled across the UK. In 2020, the BPNA eslablished a Recruitment Working Group lo develop strategies lo encourage junior doctors to consider a career in paedialric neuralogy. Various initiatives have been implemented to aid prospective trainees in making successful application8 including a careers page on the BPNA website with webinar5 on applleaiions and interviews and general topics in paediatri¢ neurology. Feedback on these sessions have been very positive overall. 1.4. Assessment and Su rt for Existin Trainees All irainees receive an annual virtual CSAC progression inlerview. In the past year, mosi trainees have been making good progress. There are challenges for some trainees to access Outpalienl activities in specifie centres and Ihe Neurology CSAC have been supporting the locRI leams to address this. A shortage of consultants IT] Substantive posts has impacled on tt]etr ability to train in some cenlres. 1.5. S cial Interest module in E ile The Neurology CSAC have rewritten the Special Interest (SPIN) Epilepsy curriculum in 2022 and this has now been endorsed and signed off by the RCPCH, The BPNA have supported SPIN trainees by creating a group for trainees, which is closely aligned 10 the neurology GRID trainees group, but with a locus on epilepsy SPIN competencies. A successful study day took place in 2025 with fijrther annual evenis planned. 1,6. Assessment of 'Non-Grid' Trainin Doctors who have noi completed the UK paediatric neurology GRID irainin8 programtne, but who can show they have knowledge, skills and experience equivalent lo the approved curr2¢ulum, can request entry on Ihe GMC specialty regisler via the Certificate of Eligibility for Specialist Regisiralion (CESR) rouie, if part of their training was done overseas. The Neurology CSAC has a role in evaluating CESR appltcations. If the GMC approve the initial applicaiion. the Neurology CSAC will review the neurology component of their training and deterniine whether it 1$ equivalent to thai of a UK GRID trainee. Ts'pically, only training in Ihe 5 years prior to the CESR application ean be?¢onsidered and if suc¢essful, the applicanl will be entered onlo the GMC specialist register. If a trainee cannot apply for portfolio pathway accreditation, they could previously apply to the CSAC to detemine whether their Iraining has been 'equivalent' to thal of a UK GRID trainee, and obtain a letter of equivalence if successful. This roule did not allow entry to Ihe GMC subspeciality register but provided assurance to ernploying T￿St$ Ihal Ihe candidaie's training and competencies have been reviewed by the Neurology CSAC. Unfortunalely, this rouie is no longer available to pursue at presenL unless a candidate has already commenced the process before JanU￿Y 2025. 1.7. A val of New Posts Job plans for all new consultant paediatric neurologist posts submitted by hospitals to Ihe RCPCH for approval are reviewed by the Neurology CSAC. The Generic Guide ￿ Consultant Paediatric Neurologisi Job Planning, published by the BPNA in 2018, has been invaluable in supporting centres in ensuring their jobs are sustainable and will allow new consultanls to meet the needs of children and young people with neurological disorders. Final approval for consulianl PaedIa￿1C neurology jobs is given by the RCPCH Training Services team. Page 4

British Paediatric Neurology A￿O¢RatiOn Report of the Trnstees for the Year Ended 31 March 2025 2. Edmealion 210 BPNA faculty in Ihe UK and overseas directly contribU￿d to the development and delivery of courses during 2024-25. This demonstrates the strong motivation and engagement of faculty, and the trustees wholeheartedly appreciate this commitment to teaching and training. The BPNA short courses run either in a virtual or face-tO•face setting. 2.1. Paediatric E ile Sv Trainin PET teaches safe standard epilepsy practice to clinicians, using consensus-based, peer-reviewed, standardised materials linked to iniernalionally recognised clinical guidelines. Iniroduced lo improve standards of care of children with epilepsy. we aim to deliver courses throughout the UK every year. 6 x PETI (l-ddy COUT&e), 6 x PET2 (2-day course) and 6 x PET3 (2-day course). PET Since 21K)5 10 31 March 2025, 13,599 UK clinicians have altcnded ts PET c(Trurse {2024-25=783; 2023-24497" 2022_23=726). contributing lo improving thc standards of diagnosis and managemenl of children with epilepsy in the UK. The PEfi course materials were updaled by a tearn of inlernational clinicians in March 2023. The upd&ted PETI materials were used in the UK from May 2023. The PET23 course materials were updated by a team of illlernational Clinicians in November 2023. The updaied PET23 matcrials wcre used in the UK from June 2024. A Consultant Pdediatrician with a special intcrest in epilepsy is employed for 4-hours per week to manage Course development. In February 2025, the PET Foundation course materiaIs were laun¢hed, which have been designed by BPNA and ESNA for specialist nurse or paediatricians with expertise in epilepsy to deliver face to face small group teaching in local non-health seiiing such is schi)ols and nurseries. These Mat￿1a]S are free to access via the BPNA website. In 2024-25. the BPNA also launched a new PET course, PET4ward, designed lo support continued professional development An paediairi¢ epilepsy. This 24lay course builds on the PETI, PET2 and PET3 courses and is aimed at healthcare professionals who wish to stsy up to dale with emerging and evolving topics in paedialric epilepsy. Attendance on all three PET123 cours¢s is a Prerequisi￿ for PET4ward. Previously il was recommended that PET123 attendees repeat Ihe series every 5 years to maintain C￿￿ent knowledge. PET4ward now offers a slrearnlined and efficieni alteTnative by consolidating essential updates into a single convenient course. The first PET4ward course ran in April 2024. Attendance numbers are included wiihin overall PET course aitendance specified above. 2.2. Children's Headache Trainin CHaT This one-day course is delivered by paediatric neumlogists and paediatricians with expertise in the management of headache. The purpose of CHaT is to improve knowledge and skills amongst health professionals who care for children and young people wilh headache. CHaT was xdapled for virtual delivery d￿rIllg the coronavirus pandcmic. In 2024-25, lour virtual CHaT Courses were held. Dwing 2024-25 CHaT welcomed intcrnalional attendees fTam Australia, Gcrmany, Hong Kong. Jsracl, Netherlands and Sweden. CHaT course rnaterials wete updated by a UK in 2024. Since 2012. 1,827 clinicians bave attended CHaT (2024-25=166- 2023-2LI 63- 2022-23=198- 2021-22=138). 2.3. Neonalal Ncumlo Assessment and Trcatmeni FAlucation NeoNATE Infants born at term or premalurely are susccptible to neurologiLdl cnnditions whose long-temi outcomes can be much improved by eflcctive early recognition and intervention. This practical 2-day course was introduced in 2014 to provide training for paediatriciaus and neonalologists ￿Ing for newl)nrn infants in dislTiCt general hospitals. It is delivered by paediairic neurologisis and neonalologists, and this unique course gives a complementary perspective on a wlde range of neurological conditions. Page 5

British Paediatrlc Neurology Assoeiation Report of the Trus¢ees for the Year Ended 31 March 2025 NeoNATE course materials were updated by a UK in 2024. The NeoNATE course was not adapted for vimial delivery and no course5 run during the pandemic, between 2020 - 2022. In 2024-25, NeoNATE ran two courses held in a faee-to-face setting. Since 2014, 770 clinicians have attended NeoNATE {2024-25=62- 2023-24=72. 2022-23=80. 2021-22=0). During 202£k25 NeoNATE welcomed international attendees from Belgium, Hong Kong, Iraq, New Zealand aud Saudi Arabia. 2.4. Ex rttoEx ert Internalional keynole speakers and UK faculty deliver an annual 2-day course. providing continuing professional developrnet)t for Consultant PaediatTiC Neurologists frojn the UK and globally. On alternate years, the course focuses on Epilepsy 01 Movement Disorders. In 2024-25. 34 people atleuded Expert to Expert.. Epilepsy. with inletnational attendees frorn Egypt {2), Flong Kong (l). Malaysia (2) and Swcden (l). Thc Tjexl Epilepsy coursc is due lo take place in 2026-27. 2.5. ApDroachi Children's Tone (ACT Children with abnornial muscle tone deserve prompt recognition and timely access to appropriate inve8lig2tion and IreatmenL particularly with the availability of new therapies for neuromuscular conditions and cerebral palsy. In view of this, the BPNA developed a short course on lone management in children called 'Approaching Children's Tone, (ACT). The ACT course was developed for virtual delivery. Since the running of ihe ￿￿51 ¢ourse in 2021k21, 417 Clinicians have attended ACT (2024-2547; 2023-24=128. 2022-23-94. 2021-22-92). 2.6 A¢ute Paedialric Neurolo It is estimaied thai about a third of all paedialric emergencies are neurological. We are aware of the volume of children attending emergency deparnJ)enls with neurologt¢al presentations, and of the anxAeiy thls can create for the receiving paediatTicians and irainees, who often feel inadequaEely trained in acute paediairic neurology. In view of Ihis, the BPNA in collaboraiion with the Association of Paediairic Emergency Medicine developed a l -day course called Acute Paediatric NeuTology. The Acute course was developed for virmal delivery. Since the runT]ing of the first course in 2021-22, 265 clinicians have attended Acute (2024-25=66. 2023-24=73. 2022-23-91; 2021-22=35). 2.7 Movement Disorders Education MOVED Unusual movcmenis iu children Call sometimes be diffiLuli to describe and LILtegorise. MOVED is a 2-day course which aims to cover a broad spectrum of movemenr disorders that aTC seen in children and will place emphasis on descripliun, diagnosis and initial Tnanagcment of Ihese condilions. This newly devcloped coursc has becn adapted frotn tbe previous Expert ti) Expert.. Movemeni Disorders course. Since thc ￿nn]llg of thc first rourse in 2023-24. 90 clinicians have attended MOVED (202￿25=s5. 2023-2L35), 2.8. Disiance Lcarninu in Paedialric Neurolo Introduction Disiance Learning (DL) provides syslemaii¢ and comprehensive learning. delivered online for trainee paediatric neurologists. paediatricians and esiablished specialisls. The course covers the whole of paedialric neurology and participants may enrol for one or more units. DL fees are differeniiated by country a￿ording io the World Bank economic classification to widen access to doclors worldwide, in line with BPNA charitable aims. During 2024-25, 175 dociors enrolled from 32 counlrie5, with 119 enrolling from high income countries and 56 from low/middle income countries. Showing how DL is a comprehensive learning resource for the international community. Page 6

British Paediatric Neurology Association Report of the Truslees ror the Year Ended 31 March 2025 Dislance Leorning complements BPNA short couisesy providing depth and exiending the knowledge gained at a one- and IwoThday courses. Working with Tespective short-course developrnent teams, explicit links are being provided in DL units to reinforce the learning provided in the rela￿d short-courses. Thus, we encourage.. PET attendees to Study Unit 6 Epilepsy - NeoNATE attendees to study Unil 2 Neonatsl Neurology - CHaT allendees lo study Unit 12 Headache - ACT aiiendees lo study Unit 5 Neuromuscular and Unil 4 Central Motor Disorders Acute Paediatric Neurology attendees lo swdy Unit 13 Acute Paediatric Neurology aiin content Distance I*arning is hosted on the Moodle platfomi. A Consultant Paediatric Neurologist 15 employed for 4-hours per week io direct and oversee the conslani revision and reMTiting process. The Distance Learning Steering Group, consisting of one/ two experts per unit. meets Iwice per year.ln the last year Distance Learning Officers have been added to support Ihe updates. These are Irainees or early career consultants with an interest in certain units that have time to support the updates with the leadslexpens of those Units. Disianee Learning development has a reserve 10 fund development for updaiing Units and paying for the external Moodle plaiforn) provider (Titus Learning)2022-2025. A new agreement will be in place with Moodle plarforni provider Titus Learning from 2026 onwards. Enrolmenls During 2024-25. there have been 654 enrolmerjis on distance learning units. by 175 people from 32 countries. The highesi proportion of these enrolrnents are from the UK, 52.57% (92 of 175). Acknowled ements We are indebted lo the Consuliant Paediatric Neurologist volunteer tutors in the UK and globally, who give their ttme to luior sthdents through the course. We give enomou,s thaDks io all those Consultants across the subspecialties who eontribule to the COUTse content development, including preparing and giving BPNA webinaTS. 2.9. Webinar Lecture SeTies Covid_19 led to a change in trainee's working patterns that resulted in them having restricted access to appropriate teaching. In response, the BPNA Presideni launched a Iree weekly Webinar Lecture Series. BPNA webinar lecture series was launched as a free weekly virtual learning resource for child health professionals, in particular those working in paediatric neurosciences worldwide. The first lecbjre was given on 14 May 2020 and leciures have been delivered weekly up urjtil Seplernber 2022, with a couple of short breaks for holidays. Since Ociober 2022 ihe webinar lectures have been delivered on a monthly basis with focus on special interest Londition topics ihat the BPNA Special Interest Group Chairs suggests. This would not have been possible without the genern51ty of BPNA members giving their time. We are grateful lo them all for preparing and delivering such excellent lectures on wide Tange of topics and for remaining until all the questions have been answered. Recordings of lectures are available in the BPNA members, area and are also provided on ihe distance learning platfonn for enrolled studenis to aecess. Page 7

British Paediatric Neurology A&soci&tion Report of the Trustees for the Year Ended 31 March 2025 During 2024-25, the webinar lecture series h&s been attended by both trainees and consulianis worldwide. 514 doctors and allied health professionals attended 6 BPNA monthly webinar lectures. Since 2020, the BPNA has successfully delivered over 100 webinars. However, a gradual dccline in attendance has been observed as well as increased challenges for STG Chairs in sourcing speakers and relevant topics. As of January 2025, webinars are organised periodically and in collaboratinn with Ihe BPNA Distance Learning Lead, when there is a specific topic that needs lo be addressed. However, SIG Chairs and Secretarles and BPNA members are en¢ouraged to reach oul lo us if they identify topics ihat they feel should be presenied io the BPNA community. The webinarq will be reviewed again in frequency during 2025126. 2.10. International Short-courses In 2005, the BPNA developed Paediatric Epilepsy Training ￿ET) courses to train healthcare workers to beiier diagnose and treat children with seizures. PETI is now attended by almost every paediatrician in the UK and the courses have also been launched overseas. setting a gold standard for epilepsv care around the world. Outside of the UK the programme c￿￿en(lY runs in.. Australia, Brazil, Colombi4 Ghana, India, Kenya. New Zealand. Singapore, South Africa, Tanzania, Tunisia. Uganda, Zambia and Zimbabwe. In 2022, the World Health Assembly unanimously raiified the WHO'S Intersecloral Global Action Plan on epilepsy and other neurological disorders. PET conlribute.g to slrengthening the health workforce. one of the Plan's key levers for change. We were pleased lo launch th¢ French Iranslalion of PET iti Tunisia this year and are graleful to all of those who contributed to ihe translation of tbe course malerials. We were also granted an extension to the grant from Global Health Partherships (formerly THET), which has enabled the expansion of PET in Ghana and Kenya. The grant is awarded on behaIf of ihe Department of Health and Soci21 Care and its extension is promoiing the sustainability of PET in each country. This was the third year of BPNA'S laiesi four-year partnership 12022-2026) with the Iniernational League Against Epilepsy (ILAE), which was formed to facilitaie ihe roll-out of PET worldwide. The men]orandum of understanding has a value of $278,844 over that time and reflects our organisations, shared commtlmenl to iniproving care for children with epilepsy. Trnslees are cognisant of the need io ensure international launch and delivery of eouTses is sustainable and that all courses rneei OUT defined quality Standards. The following internaiional partners support us in these ainis.. - Australia - Australia and New Zealand Child Neurology So¢iely Brazil - Liga Brasileira de Epilepsia Colombia - Aso¢i4tcion Colombiana de Neurologia Infaniil and Universidad de Aniioquia Ghana - Paedialric Socieiy of Ghana Indta - Raindrops Children's Foundation Kenya- Kenya Paedialtlc Association - New ZeAland - New Zealand League Agdinst Epilepsy - Singapore - KK Women's and Children's Hospital South Africa - Paediatric Neurology Development Association of Southern Africa - Tanzania - Paediatric Association of Tanzanid - Tuntsia- Association Tunisienne pour le Developpement de Épileplologie Uganda - Uganda Paediatric Association Zambia - Zambian Pftediatric Association - Zirnbabwe - Paedialric Association of Zitnbabwe Page 8

British Paediatric Neurology A&%ociation Reporl of the Trustees for the Year End¢d 31 March 2025 The total nurnber of attendees Ouiside the UK and Republic of Ireland is 8,314 (PETI 6,558; PEf2 762- PET3 = 327; IPET = 274. Trained as faculty = 362). The table below shows totals for countries where PET was rnn in 20￿25. PETI PET2 PFf8 PEn PET2 PEf3 Comblned 27 23 194 71 23 140 488 28 540 272 140 232 543 543 86. 1872 1872 307 53 21 801 131 21 953 36 36 36 56 473 289 762 20 498 498 38 271 46 46 32 202 202 40 102 102 28 76 76 6461 137 5874 519 256 full attendance lists have not.been obtained frorn our partners in India. Malawi- No formal partnership exists. Course was taught by SouthAfricen and U8andan faculty. 2.1 l. Evaluation of edu¢alionaJ actlvlties BPNA'S edu¢ationa] activ2ties are designed lo promoie the health and well-being of children with neurological disorders. We are commiited to eva]ualing them to ensure thai ibey do so and to adapting them on an ongoing bagig. Afier Completton of any of our educationdl aclivities, learners are required to complete d feedback forn) to as5es,g their level of satisfaction with the course. At PETI courses, learners aiso complete a pre- and post-course quiz io assess knowledge-gain. and, six months laier, a follow up survey to estsbltsh the changes that they have made lo their clinical pracuce. These data have been analysed by a group of researchers from the BPNA and the University of Dundee and, in 2024. they were published in a paper entiiled Reducing epilepsy diagnostic and ireatmenl gaps: Siandardized paedialric epilep8y training courses lor health Care professionals in the Journal Developmenldl Medicine and Child Neurology. We found that 98C/o of PLTI delegrfltes change their peTsonal clinical praciice after attending the course and 64% change their clinica] setVA¢e. 68% iniiiute or improve epilepsy teaching at Iheir hospilal. We are working with the University of manche.ster to futthcr refinc our evalualiun meihuds for the PETI courxe by using a Llinical behavIuural-ch￿ge methodology to further understand the impact of the course. It is hoped Ihdt these refined cvalualton tools can be adapted and applied lo other BPNA shorl courses. Annual .Scientific Conference Oversight of the sciencific connl of the annual meeting, including abslracl scoring tmd awarding of the MacKeith PriLc, rests with the Re5ear¢h Committee. The 51 st annual sctenlific n]eeting was hosted by Oxford and held as a hybrid event in January 2025. There were 861 delegates from 55 countries. Technology facililaied high delegate numb¢rs (2024 Bristol=726,. 2023 EdinbuighJl6- 2022-941. 2021=1,134) and ¥ei)graphic access. OppOr￿nitIeS to learn were provided by 23 oral presentations and 250 posiers (selected from 289 abstracts submitled). 7 keyno￿ lectures. 4 clinical practice sessions: and 6 sponsoted symposiums. Page 9

Britlsh Paediatrlc Neurology Association Report of the Tn￿tee$ for the Year Ended 31 March 2025 2025 Prizes were awarded to.. Dr Elizabeih Radford (University of Cambridge) The Ronnie Ma¢Keiih Prize. Awarded to the person who has made the most significant contribution to paediatriL neurology as judged by published work and who is <40 years old or within 5-years ol obtainillg ccr. Dr Jonaihon Holland (University of Cambridge Department of Clinical NeurosciencL"s) Best oral presentation by a trainee. Dr Gayathri Varnia Narendran (University Hospitals of NortlTr Midlands) Bcst oral poster presentation by a Iraince. Dr Emtnan Ahemad (Great Ormond Streei Hospital. London) BPNA 'BA￿A, AwaTd for Fxbulous Trdinee Action.A warded to the Irainee who has best conlribuled lo service improvemenl which significantly impacted on their local andlor national practice or any other innovative conlribulion. Ms Nandika Ramamurthy (Newcastle University) Besl medical student presentation. Dr George Davies (Univer.sfftty Hospitals Bristol and Weston, Bristol) Developn]eni Medicine and Child Neurology (DMCN) Best Ani¢le by a BPNA Trainee Prize. Dr Thomas Leyland {Roy21 Belfast Hospilal for Sick Children) Best online poster presentation by a trainee 4. Patient and Public Involvement (PPI) We had 10 paediatric neurology relalcd chaTlties or associations attended the conference and take up a physical sland to engage with BPNA members and Ihe other altendees. Visiiin stand stam c.ards To motivate delegates attending the conference physically to vlsit and engage with our cxhibiti)rs, slamp cards were be pTovided. Delegaie5 who collected .5 siamps fiom chillity exhibiiors, had a chance to win up to 4 £50 voucher5. The aim was to opcn up on the opportunity foi chariiies to engage with aiiendees at the conference and identify opportunitics to improve the lives of children with neurologiLal di80rders. Each BPNA Confeience venuc has its challcnges of where stand spaccs can be localcd, and Ihe BPNA airns for charitie5 to have as much inyolvemeT]t as possible with their sland location. Feedback was received Ihal stsmp cards had a positive benefit bul there was room for improvemenl on engagemeot. The BPNA look forward io hosting ihe charities again ai Ihe 2025 conference. ch￿71 , Videos al the sessions The BPNA looked at ways for the Charities lo get as much exposure ds possible for the delegates attending. This year the BPNA asked ch￿IlIeS to produce a 90 second video, two of which would be played ai e￿h BPNA session. 13 Charilies look the opportunity to promole their chftrity via a video at the Siart of the session and they were very well recetved. Page 10

British Paediatri¢ Neurology A￿o¢latiOn Report of the Trustees ror the Year Ended 31 Mareh 21)25 Other activities Workin Grou A PANSPANDAS Working Group was set up to dlscuss and liaise with PANS PANDAS UK in pmducing d PANS PANDAS WoTking Group Statement with other colleges and groups. This was published in FebnRary 2023 and addresscd the cuThent vwiation across the UK in thc management of patients presenting with PaediatriL Acutc-onset Neuropsychidtric Syndrome (PANS) and Paedidtric Autoimmune Neuropsychiairic Di.sorder5 Associaled with Streptococcal Infeciions {PANDAS). Since then a PANS PANDAS Clinical Guidelines DevelopmeTJt Group has been set up who have been mceting o which various BPNA members have been involved in the dcvelopmenl. Dru ResAst￿l E ile Stakeholder En crnent meetin The BPNA has bcen meeting ye￿lY since 2023 with farnilies, charities and other stakcholders to keep discussing varivus matter on the challeDges An managemenl of children with treatment-resistanl epilepsies. The meetings happen every September wilh plans to have one in in 2025. The BPNA ¢onstsntly looks to expdnd the PPI ihroughout the organisation as parl of the charilable aims. Request have been made for PPI representation in the special interest groups, course development and as many other a¢iivities as possible. As well as trainees should be facilitated to WOTk with PPI and social media. We proposed increasing ihis area going forward. 5. Research The BPNA research commitiee has a remit for oveisigbi of the annukl scientific meeting as outlined above, as well as for the speciality paediatric neurology session at the annual Royal College of Paediatrics and Child Health meeting. The research committee also oversees the development of research within the organisation lo the benefjl of children with neurological disease. The BPNA Research Committee is chaired by Dr Sam Arnin. Members have a wide range of ¢linical and scieniific expertise and come frorn a broad range of UK and Irish Paedidtric Neurology Centres. The research committee has been working to develop the agreed research Stralegy of the BPNA, focused on building research Capacity within paediatric neurology and promoting research training within the paediatric neurology traincc comrnunity. Thcre is also BPNA ResearL'h Cornmitice representation on the editorial board of Mac Keith Press for the Developmental Medicine and Child Neurology (DMCN} journal. Two ReSe￿h Commiiiee members and three other BPNA members. -5. l British Paediatric Neurolo Survcillance Unit BPNSU In 2006, the BPNA set up the BPNSU to iarget surveillance of rare neurological Londitions in a cost-effeciive and efficient mdnner with Ihc samplL population being UK consultiuit membcrs of the BPNA. Since 21i06, 28 studic$ have been conducted using BPNSU. Dr Sukhvir Wright has taken over from Prof Richard Chin as BPNSU Leail in the ReseaTch Commiltee. During 2024-25, 1 projeci w&8 added onio ihe BPNSU syslern (2024-25 = 1. 2022-23 0, 2021-22 = 1, 2020-21 -1, 2019-20=1; 2018-19=1. 2017-18-3). As of 31 March 2025 four projects were active on BPNSU system. BPNSU fees were increased in 2020-21 to £1.200 for up lo 2-years. which is still signlfjcandy less than other surveillance s￿di¢s. Addilional year5 are charged £6￿ per annum. The BPNSU websile has been moved Inhouse since summer 2023 and has been managed by BPNA, achieving continued updaie tor the BPNSU email Iisi and optimisation of relurns by ihe Membership Manager. Emails are sent out once a month for noiificalions of new siudies. Pagell

British Paediatric Neurology Association Reporl of the Trustees ror the Year Ended 31 March 2025 In 2020-21, an audit of all past studies was Cdttied out. Since 2014. there have been 15 conference abstracts and 10 peer-Teviewed publications resulting from BPNSU studies. Journal publications hdvc been in DevLlopmental Medicine dnd Child Neuiology, tscumlogy, and Lancel Child and Adolescent Health. One PhD was awarded. and one projecl reported 4 invlled inleEnational taIks in whiLh BPNSU data were part of thc presentation. There wcre four SUCLes8ful granl applicalivns arising fium BPNSU studies. with a lolal grant income of £1,237,949.. 1 MRC Dcvelopmenlal Pathway Funding Scheme award, l NIHIUGOSH Clinical Fellowship, l KESS2 (Knowledge F.conorny Skills SLheme) Sthdentship. and a donation from the Alicrnating Hemiplegia ol Childhood UK Charity. Public engagement varied from parenlaI groups infoTniing study design. results itrfoming genetic counselling for families, io results being presented or plallned lo be presented. In 2021_22, Ihc BPNA revicwed b￿er$ for applications and implemented the BPNSU Grant AwaTd. It was agrecd by thc BPNA Trustces to produce a BPNSU Granl Award for up to a 2 ycar study. This i.s equivalent to the Lost of £1200 which would cover the cost of a study so as lo supporl ihis charitable airn. This grant would be eligible for a BPNA membeT who is otherwise a trainee or newly appointment consultant within 2 years of qualifying. The puw)se of the award is io promote research amongsl junior members of the BPNA and lo help create future researchers in paediatric neurology. Recent aims has been lo promote BPNSU to develop our relationship and ty to collaborate with ihe Brilish Paediairic Surveillance Unli {BPSU} which is pan of Ihe RCPCH. This is due lo having similar Objectives and is ongoing. 5.2 Paediatric Neurolo Fellowshi A parmership was established in 2015 with Action Medical Rese￿Ch {AMR) lo jointly fund a 3-year AMR-BPNA Research Training Fellowship. Voluntary donations of members and income generated from sponsoTed symposix al Ihe annual conference fund thi5 fellowship. The second fellowship has been awarded 10 Dr Michael Eyre in his proje¢L Developing magneti¢ resonance measures of neurobiological dysthn¢iion in early recovery from NMDAR-anubody encephalitis,. Michael will investigate if advanced IrfRJ techniques can help predici recovery from NMDAR-anubody encephalitis in children and young people, Paving the way for new treatment approa¢hes for the condition in future. The third fellowship was advertised and awarde4J to Dr Jonathon Holland, commencing in Autumn 2022. In his project" Aultiple sclerosis.. assessing nerve repair in children lo find out if Ihey could benefit from new trealments, Jonaihon will aÈm 10 find out whether children with MS could benefit from potential new treaiments c￿￿entlY being tested in adults. A fourth Fellowship was advertised in SumTner 2024 with the aim to commence in September 2025. The fourth FLllowship was dwarded to Dr Evangelia loannidou for the PTuject- 'Rasmussen's enccphalitis.. investigating the underlying causes of this rare childhood brain inflammutiijn Éo improve diagnosis and trcatment,. Previous AMR BPNA ReSt￿ch Training Fellows: 2016-19 Dr AEKTrStolos Papandreou Neurndegeneraiive disoider.s wilh brain iron accurnulalion - finding new trealments. 5.3 BPNA Conference The BPNA Research Committee revicw. score and select subrnitted abstracts, sponsored symposium and the Ronnie MacKeiih Pri7£. Mac Kcitli Press co supporE the Ronnic MacKeith 14ize and a150 qUPPOrt and select the Developmental Medicinc and Child Neurology (DMC.N) Be,st Article by a BPNA Tratnee Pri£c. Prizes are also ch05cn and give by the BPNA for the Best PostCT by a Trainee Prize, Best PosteT Audio Narrative by a Trainee Prize, Best Oral Presentation by a Trainec Pri7£ and Best Medicdl s￿de￿I Presenthtion. A new PriLe 'Besl Presentaiion by an Allied Healih Professional, has been added staring from January 2026. Thi5 prize will be awarded lo the allied health professional (specialist nurse, psychologist, neurophysiologist, physiotherapist. sPe￿h therapist, etc) with the besl pre5enialion, either poster or oral. Page 12

British Paedfiatric Neurology Association Report of the Trustees for the Year Ended 31 Mareh 2025 5.4 Read of the month and Traince a er of the rnonlh As parl of the BPNA Newsleltcr, evLry month, a different member ol the BPNA Research Commiitee will cbvose a recently published, tnpicdI paper relevant to Paediatric Ncurology. Neurodisability or Neuroscience, that they think would be ol interes1 lo Ihc BPNA membership. Also every month, a recent publication Ihat has either been led by a BPNA Trainee (or where a trainee has provided significant input) will be highlighted. 6. Professional Su There is a high demand for Professional Support. One full time staff member (Membership Manager) oversees the department. Dealing with membership requests, mentoring capacity, organisation of meetings for Special Interest Groups and supponing Trainees with their development. The Professional Support Officer (Trustee) is responsible for the department and meets regularly wilh the Membership Manager and Dlrecior to make sure areas that need developmeni are progressing including job planning. mentoring, charity involvement (PPI), Census and Paediatric Neurology re¢ruithient. Duting 2024 the BPNA New Grid Trainees Support Prograrn was launched. where senior gTid trainees or newly qualified cunsultalils offer guidance to new grid trainees. The progran] is designed to offer infonnal pecr-I￿peer advice and guidance for trainees who are new to the Grid trainin¥ program. The Prim2￿ aim is to help trainees navigale their transition, address common concerns. xnd connect with a supportive nenvork of fellow professionals. 6.1 BPNA membershi Membership numbers have Ancreased steadily during 2024-25, supported by the Membership Manager, Katerina Roumelioti. A new category of rnembership 'Allied Health Professional, was introduced in recent years. This caiegory has minimal subscription fees to encourage engagement and no voting rights. The BPNA also added Medical Student membership wilh £0 fee to engage wilh young people with an early inlerest in Paediatric Neurology. Criteria to be accepted is a confumarion leiier from associated University that is resent each y&gr for membership renewal. BPNA Member5 March 2025 700 stso 49 S5 7Q 300 709 Irj) 2015 20J6 7017 2018 2019 2¢21 2012 1073 1924 I￿$ •O¢£llnaiy rwOv*isw41 Str￿r * Honorwy ¥ AHP • med￿.￿ 51 Page 13

British Paediatri¢ Neurology Association Report of the Trustees for the Year Ended 31 March 2025 Member8hip numbers Ordlnary Overseas 386 382 376 81 75 72 Train 118 125 126 Senior 65 66 70 Hontsrary AHP 63 51 Medlcal Student li Totsl 732 715 705 6.2 Mentorin and Team Su In 2015-16 Trusiees identified a need for members to have acttss to mentoring services, and it was agreed that the BPNA should Contribute to fulfilling this need. The mentoring Programme began in 2016. During 2020-21 the mentoring programme was expanded to paediairic neurology and Neurodisabiliiy GRID trainees within 12 months of CCT lo provide additional gupport through the pandemic. As of 31 March 2024 ihere are 42 BPNA members volunlecring as mentors (2023-39) wilh 29 mentees (2023=50) with some mentors now taking on two mentes. In November 2023 BPNA commissioned a Menior Consulianl to deliver a training day foT mentors for a fourth time. The traintng taught differeiit mudels of. mentorship and was very well received. The aim would be lo do this every year but reviewing develi)pment foi both ]nentors and menlees and how this area can evolve. DutiT]g 2023 the mentoring prograrnme wa5 expanded for morc ￿nIOr CPNS who requestcd more mcntors to SUPPOTI Ihem through care£r stages, such as post moves, return fmm parental Icave, reiirement elc. During 2024 it was decided to introduce two additional training sessions: one for menlees interestcd in becorning mentors. and another for senior meLtors. Both sessions are scheduled to be delivered between 2025 and 2026, wilh the inEention of nMking them annual evenls. The mentoring and mentee program is being reviewed in was it can b¢ developed for th¢ workforce of the BPNA membership. Page 14

British Paediatric Neurology Association Report of the Trustees for the Year Ended 31 March 2025 Inviied Reviews In Support of the BPNA charitable aims. BPNA Invited Reviews offer assistance to healthcare organisalions in addressing concerns and challenges relaling to care for children with neurological conditions. "The primary purpnse of an invited review is to provide expert opinion and external assurance around (wality of care Ihal may lead lo improvemenls lo patient sately serviLc provisiun. Invited reviews arc designed to facilitate refleclion and learning." Academy of Medical Royal Colleges 'A framework of operating principles for managing invited reviews wiihin h¢&lth¢are' (Mar¢h 2022). BPNA Invited Reviews are conducted in accordanc¢ with the principles set out in the Academy of Medical Royal Colleges (AOMRC) 'A frame￿'0rk of operating principles for managing invited reviews within healthcare, (March 2022). The BPNA has produced A Guide to BPNA Invited Reviews, ai'ailable on the BPNA website. which explains the structured, ¢l¢ar and consistent process that we follow. h(tpS:Ilbpna.org.ukl￿age=inVIted-TeVIews No Invited Reviews happened thi5 year. 6.3S cial Jnlerest Grou Special Interest Gmups meetings continue operating on a hybrid model makes it more accessible for people to join online or in person depending how their meeling is arranged. Face-lo-face mee(ings during the annual confcrcnce returrted in January 2024, howeveT, due lo the siLe of the groupy, online mectings will continuc to happcn throughoui Ihe rest nf the yeaT. as it is easier forn]embers ro aiiend. The BPNA also updated their website for each SIG page lo inforni about Trials and resource documcllts for thcir members. SIG 6.3.1 British Paediatric E 'le Grou Members of this Special Inleresi Group have particular expertise in childhood cpilepsy. There are oveT 100 mernbers which includes paediauic nellrnlogists, paedialricians with an In￿reSt in epilepsy and clinical nurse specialisls. Three meeting.s have been held in March and Augu.41 2023 and January 2024. The focus of Ihe meetings has been on the development and implementation of guidelines for epilepsy in children. to share updates in audit and research in paediatTiC epilepsy, to explore opportunities for the professionals to network and lo discuss anonymised complex and educational cases. The BPEG (British Paedialric Epilepsy Group) Chair and members have contributed ro the following particular aspects of childhood epilepsy.. Page 15

British Paedlatrle Neurology Association Report of the Trustees ror the Year Ended 31 March 2025 Cannabldlol and CBMPS Ongoing liaison with RCPCH, NHSE and stakeholder charities on issues related to prescription oficannabis-based products for medicinal use in children and young people wilh epilepsy. We al80 have BPNA CBMP group mettings to review press and media request5 about CBMPS. Sodium valproale Since ihe announcement of MHRA staiement on new re.8trictions on the prescription ol sodium valpruute, we have actively engageil wilh relevanl stakeholders such as epilepsy charities. Association of BTitish Neurologists. and OPEN-UK io discuss potential implications. In collaboration with OPEN-UK, w¢ have written a guidance docurnent for BPNA members on prescription of valproat. We also fonned a working group to addres& thc issue of changes to sodiurn valproate prescription and to support BPEG members. Stakeholder Charities Enga¥cmcnl wilh stakeholder addrcssing all Issues relating lo care of children with epilepsy. We have had 2 positive annudl nieclings with slakeholders, nexl one scheduled in September 2025. NHSE Epilepsy Oversight group Ongoing contribution to NHSE cpilcpsy oveisight group and implemenlalion of national bundles of care for patients with epilepsy as part of CYP Transforn)ation Programme. Fa¢ilitoting audits and research In paedlatrie epllepsy BPEG provides the platforni for colleagues from across ihe UK to present their research, facililate collaboration and selting up a dedi¢at¢d page on BPNA website with inforn)Rtion on epilepsy research projects. BPEG is supporting national audits on use of specialist tnedications like fenfluramine and cenobamale lo gather real-world data on use, effjcacy and safety to inform practice. Cliniol Nurse speeialists and paediatric neurology trainees BPEG have eiicouraged contribuiion of clinical nurse specialists and Advanced Nurse Practitioner in childhood epilepsy and requested for representaiion in the group. BPEG have encouraged participalioT] of pdediatric neurology trainees and epilepsy SPIN trainees and requested for representation in the group. Additional meetings regularly atiended with eontributions (rom BPEG: Epilepsy 12 Audit piugrdnime. Open UK Nelwork Meeting. Epilepsy Programme Board (lcd by RCPCH). RESCAS. 6.3.2 CcrLbrovasLular S cial Inleresi Grou We continuc 10 woik alon¥side the Stroke association in highlighting Ihe inequity of stroke care in some regions and improving acc&gg io treatments tn a iimely manner. We are forniing new relationships wilh CcrcbTovascular collcagues aring lor adults and encouraging joint working particularly in acute stmke but also considcring Iianstion Care. This includes liuison wilh BIASP and ABN. We hope lo work with ALSG io work on a "brain attack" simulation and hopefully including this on the APLS pathway in due course. The group mel in the last year and discussed ihe findings of the "Stroke readiness survey" Colleagues are now able to advocate on behalf ol their own cenlres by highlighting Ihe inequily of rare in their centres. Prof Guilliams. St tATruis delivered an exciting talk on use of Tenecteplase in acute stroke which was valued by colleagues. Page 16

British Paediatric Neurology Assoeiation Report of the Truslees for the Year Ended 31 March 2025 6.3.3 Children's Headache Network CHaN CHAN has continued io remain very active over the past year to advance the clinical management, education and rebearch in primary and secondary childho(MJ headache disorders. In 2025 we resumed face lo face meetings and plan to continue Ihrice annual meeling,s remotely. We provide access for CHAN members to a CHAN messaging group for sharing research and providing mulual support for anonymised ¢lini¢al problems. A clear structure of the roles within ihe CHaN network conEinues with dedicated responsibilities to meihbers for proiiiding ¢lini¢al. research and academic updates. There is close working relationship with clinicians overseeing the 2024 update of Ihe highly successful Children's Headache Training (CHAT) course and Headache distance learning module. CHAN members are currently looking lo devel(y aTr expert-io-expert equivaleni course wlth BASH (British Association for the Study of Headache) and have submilled an application lo the BPNA for support. A drafi guideline has been sent to meJnbers regarding Ihe use of topiramate in headache disorders (both migraine and idiopathic intracranial hypertension) given the MHRA {Medicines & Healthcare products Regulatory Agency) recommendalions. CHAN is cU￿entlY in the process of working on a guideline on prophylaetic agents in the use of migraine given this change. CHAN is currerjtly looking to develop a Headache SPIN module bui feedback from the Royal College of Paedialrics and Child Healih to the National Training Advisor was that there is not a propensiiy 10 develop new Modules ai this lime. CHAN will use this lime to develop Ihe ¢utticulum pending the RCPCH'S futtjre abiliry io support the module. The CHAN network has enabled sharing of knowledge regarding research acuviiies such as mulii-cenlre studies inlo new drug treatments for migraine. CHaN also recognises ihe need to develop national registries for patients with rare headach¢ conditions to irnprove and harnionise care for children and young people across the UK and beyond. Aims foT th¢ next year Ratification of topiramdle guideline Creation of ihe prophylactic migraine medicaiion and tripthn guidelines - Launch of expen-to-experuadvanced headache symposium Regular meelings including launch of complex case meeiing - Development of headache SPIN Module curriculum pending the RCPCH'S ability to support new mixlules. 6.3.4 Fetal & Neonatal Neurolo ial Interest Grou The Feial & Neonatal Neurology Special Interest Groups has a strong educalional theme, and continues 10 provide educational meeiings iwice a year in neonalal and fetal neurology. These have been delivered virtually and draw a range of health care professionals, including Allied Health Professionals, from around the UK and beyond. The next half-day education meeting is planned for Oclober 2025. Members of the SIG group have coJ)tributed io an updaie of the NeoNATE course 2024-2025; this was led by Anthony Hart, sIG-C￿ChaIr. We are looking to in¢rease our lea¢hing faculiy tn the coming year. Now, with ihe NeoNATE course update completed, we are making good progress with the BPNA Felal Neurology course, which aims lo provide educaiional material 011 fetsl neurological anomalies and an￿naEal counselling. A preliminary programme has been produced and talks are currently being writien and reviewed. Aiiihony Hart has iniualed and leads on a collaboration with the British Association of Perinatal Medicine (BAPM) and Ihe first joitii educational eveni is a one-day conference in April 2026. A preliminary programme has been dTa(ied. If this is a successful firsi conference we aim lo hold this annually and expaiid to a tW041ay eveni. Page 17

British Paedialrl¢ NeuTology Association Report of the Trustees for the Year Ended 31 March 2025 Internationally, we have had meeting5 with perinatal neurology colleagues in the US, and plan io collaborate on education meetings and service recommendations, as well as building our contacts in Europe. We have published a 5erics of reviews on brain abnurn]alilies detected by fetal MRI recommendations for c]inical practlce with the US Perinatal Consortium. We are planning to set up joini UKIUS Fetal Neurology evening meetings whcrc thc locus will be on discussion of specific lypcs of antenalally diagnvsed brain abnormalities in an inforn]al setting. Clinically, the BPNA Executive has agreed for us to pr￿eed wilh an iniliative io develop patienc information leallels on d range of fetal neurological anomdIies, and a working gioup is being ereated. We also intcnd lo discuss how wc can collect dala on genelic diagnoses and oulcomes, which would inforni dnd improve fulure prognosiicatiQD. Members of the SIG remain resc￿Ch active in a range of ureas, including MRI appearanccs dnd neuro-developvncnt outcomes following neonatal hypoxic ischdemic encephalopathy. families, VILWS on antenatal counselling, and x new prolornia for the ncuTological examination of the unwcll newborn baby. A survey on praciice of musclc toDe regulation management in infants is cutTCJ)Ily underway. There are some changes in SIG roles: Anthony Hart will Complete his second ierni as co4hair and a call has gone out for inieresled colleagues for this position. Tony will stay on ITJ Ihe role as a senior mentor to the SIG. Brigitle Vollmer has coMple￿d her first tenn as co-chair and has expressed interest in a second terni. Raje4h Karuvatti] has compleied his first term as s¢cretary and would be happy to continue for a second term. We are pleased that two senior trainces, Hassan Shakeel, Paediatric Neurology Irainee in Glasgow, and Fadi Maghrabia, Neonatal trainee in Sheffield, will join as Trainee Representatives. 6.3.5. Inherited White Matter Disorders "Leukod stro hies cRal interest rou Dr Lydia Green took over from Dr Rahul Singh as Chalr of the Special Interest Group. New National Service for Inherited Nvhiie Matter DisoTder5 IWMD clinical re 1st NHS England has recently commissioned a new highly specialised service for Inherited Ivhile Matter Disorders (IIVMDS) and also a sepurale National IMIVD clinical registry io support this. NHSE has commissioned 3 paediatric and 4 adult centres to provide the IWMD service. NHSE has also contracted with Evelina London Children's H05Pltal which is pk￿ of Guy's and St Thomas, NHS Foundation Tnjsl, lo host the Nalional IMWD clinical registry. A core element of the regis￿ is the management of online secure dalabase that contains infOrn￿ll0n a￿ut people of all ages wiih suspeettd or confirmed IWMD. We aim to use ihis registry to support the provision of direcl patieni treatmeni and care and improvements to clinical care. This will help us 10: UnderS,￿lld the in¢idence and prevalenLe of IWMD in our population, irnprove our understanding of the natural history of various TWMDS, measure the impact of living with an tWMD for patients ai)d carers and create more awareness of thesc conditions. This regislry is unique as this is both clinician and Pdtienl driven. The primary aim of this registry is for clinical purposes. however, this registry will LL"rtainly provide Rmportdiil data for fumre research for patients within the ficld of IWMDS. Thc Tegistry will work very closcly wilh 3 other paediattic IWMD clinical service centrcs (LeedslManchester- Lcd by Professor Johll Livingstormr Dipak Rdm, Bimiingham - led by Protessur Evangeline Wassmer and Dr Amitav Parida and IAindon {Gsrr and Great Onnond Street) led by Dr Rahul SinghlDr Cheryl Hemingway) and ihc adult cenire (London, Queen Square Hospital-led by Dr David Lyncb) in collaboraiion with units in the north and Midlands. A formal launch of the IWMD iegistry service will take place lalcr in the year. Thc registry is in the piloi phase now and we expecl this will be live soon. A formal launch of the IWMD reglstry service will lake plar¢ later in the year. The registry is in the pilot phase now and wc expecl this will be Itve soon. We would accepl referrals from patients, P￿entS or carers, clinicians involved with the IWMD patients, and from neurologists, paediatric neurologists, geneiicists, melabolic physicians, geneticistg, paediatricians or any loca] clinicians involved in the diagnosis or trealmeni of IWMDS. Page 18

Brfitlsh Paedfiatrlc Neurology Association Report of the Truslees for the Year Ended 31 March 2025 Referrals will also ￿ #¢¢epied froin fetal medicine teams, when there is a sirong family history of an tWh(D and we will also facilitate rapid diagnosis for conditions where there is a treathient option {e.g. Metachromatic Leukodyslrophy). The charities Alex TLC {www.alexilc.org) and Metabolic Support UK (www.metabolicsupportuk.org) have been closely involved in the development of this registry, will continue to support the registry and will be an inte8r&l part of the IWMD regislry steering and development committee. We plan that the new service will be fully operaiional in the coming monihs. In the M&￿tiMe, if you wish lo request furtber inforniation please contact: [e-mail] 6.3.6. British Paediatric Movement Di50rder S cial Interest Grou The 1&81 year rcprc5Cnts my fmal ycar d5 SIG LhaiT, dnd Ihe final year for Raj Lodh as secretary for the group. I would like to persnnally thank Raj for all of his support and guidanLC duTing our 6 years in posl, and also to thank Ihe men]bership for their support (and indulgence!) during ihis time. It has been boih pleasure and a genuiT)e privilege lo scrvc as Chair ol this group, rewesenling as you do the broad spectrum of clinical activity in the field of movement and moior disorders. from cutting edges of advanced gene discovery and advaT]ced therapy development thmugh to system level servic¢ design and delivery for children with neurodisability. J am a better clinician now through the expctiencc of this Fole. In the 2024-2025 ycar thc SIG has rcrnaiDcd active and successful. In addition to regular virtual meetings. the SIG held a well-altended meeting at the Oxford Conference, focused on developing further research work in line with BPNA psp. Education will remain a majoT focus of ihe MDSIG. This year has seen the continuing success of the MovEd course, delivered by an expert fa¢uliy led by Dr Luclnda Ca￿. We ihank the faculty for all of their hard work producing such an excellenl educational resource. The Acr Course has coniinued to rnn with similarly excelleni feedback, with leadership of the course now transitioning from Dr Paul Eunson to Dr Kdtherine Martin. The SIG would like to thank Paul for his visionary leadership in the development 8nd delivery of ihe ACT course, providing as it does a uniquely strong voice for parents and carers in Ihe BPNA short course catalogue, Professor Manju Kurian has now been appointed as Course lead for the Expert-lo￿ExpCrt Movement Disorder Course due lo launch in late 2026. I'm sure the SIG will agree thai there is no better BPNA member beiier positioned than Manju io drive this course forward. A priority for ihe coming year is Ihe overdue re-write of Unit 4 of the Distance learntng course. Work has continued on Guideline Development. Consensus guidance on referral of children and young people for consideration of neurosurgical intervenlions has now been completed, and will be circulated later this year. Work on Consensu5 Siandards on MediLation Use in n￿nagement of Childho(Kl Dystonia project has not progressed at quite the speed hoped, but Tnot¥]cntum is duc to rcbuild in latL"1 2025. Finally, a joint project has been initialed with the Paediatric Crilical Care Society (PCCS} which will launch in mid-2025. focussed on improving the recognition and management of dystonia in childrcn and young peoplc in the Critical care environment. The SIG has now completed a large audit across several centres on the use of transdermal clonidinc patches and is SUPPOTling the development of guidance for ihe use of patches. This WOTk was prescntcd ai thc BPNA ConferenLe ITJ January 2025, and will soon be submitted for publlcalion. Work with transition has progressed, jointly with the ABN. This work ha5 focussed on identilying examples of the tyPC5 of Londitionslchildren who would usually be transitioned from Paediatric Neurology Care to General Practise. IA)cal Adult Neurology services, or to spccialist Adult Ncurology services. I am delighted to announce that from May 2025 the SIG will be chaired by Dr Ram Kumar, with Dr Claire Lundy stepping into Ihe Secretary Tole. We thank Ih¢m both for taken on these posiuons and have no doubt that Ihey will continue to grow the SIG and develop ils offer io BPNA members and work io Ihe benefit of Children oJ)d Young People with Movemeni Disorders. Page 19

British Paedlatric Neurology Association Report of the Trwstees for the Year Ended 31 Mareh 2025 6.3.7. Muscle Interest Grou The musLlc SIG works closely with the neuromuscular charities. in particular the Muscular Dystrophy UK (MDUK), Action Duchenne, Duchenne UK, SMA UK, DMD HUB. These partnerships have helped acLLlerale research funding research fellow p051s, access to clinical lrials, improved stsffiDg at PCFipheial sites for trial set up, helpcd coordinatc iegional neuromuscular networks upskilling evcnts and supported n]eetings to impruvc slandarils of care and daia collection and disscminarion. The centre ol excellence audils took place in 2023 and were awJrded io centres in 2024; 24 centre awards in to(dl- 16 to those with clinical excellenLe with rG8earch. 3 with clinical exceuence and 6 pursuing &W￿dS in clinical excellence +l- research. This year key involvements have been the announcemenl of 2 DMD therapies in December 2024. Vamorolone. a dissi)CidtC 5tcroid was approved by NICE and NHSE (10th Decernbcr 2024), an available for delivery to patients from April 17th 2025. as well as Givinostat. an HDAC inhibiior that has MHRA approval (20ih December2024) dnd part of an EAP, with NICF. and NHSE curnmitlee set for July 2025. This has required increascd input and organisation fiom trustq to delivcr these drllgs with somc Irusts struggling to meet this rcquirement. howcvci Duchenne UK have been lobbylng to help rcsolve this and most trnsls are now on board with this, however this is still a 'learning curye. and we are therefore having regular 'leams' meetings lo discus5 cases and scenarios via the neuromuscul￿ network. There have been a numher of webinars hosted by both pharma and Duchenne UK for Vamorolone. especially dsscussing switching from one steroid to Vamorolone, as well as benefits and po￿ntial risks. Involvement continues Wlth SMA UK and MDUK in helping to continue the delivery of the MDT in SMA, including Zolgensma, ri.sdiplam and nusinersen following approval by NICE and NHSE on 8 March 2021. Work continue5 to be focused on working towards newborn screening which will change ihe prognosis and outcomes for the children with SMA type l. There 18 now more research looking into the emerging pheno¢ypes of the new SMA type I children post DMT and also improved collaboration with Adult SMA Reach. All the SMA Children have been followed up arld various webinars and meetings have been held witli European colleagues on side effects and problems associaled wilh gene therapy. as well as physiotherapy forums, spinal forums with both orthopaedic and ortholists, and a phanna sponsored fornm meeting face to face planned in June 2025. From the Northsiar group. Work has been continuing particularly following the Vamorolone and Givinostat announcements and approval by NICE and EAP respectively, both non-mutation specific drugs for DMD. The annual Northstar meeting is planned and adhoc northslar meetings have been held during the year. HUB DMD. has continued close working with clinicians lo enable trial readiness and liaison wilh ihe pharn]a companies to I(￿k at what is needed per siie to conlinue iriais. Trials are now continuing and further set up of sites for new swdies have commenced. As a SIG we have continued in 2024 and 2025 to meet regularly virtually and full day face io face muscle interest group meeting Pl￿ned for 20th June 2025. Boih paediatric and adult Northsiar meetings (DMD) and paediatric and adult SMA REACH tTheetings (SMA) have continued virtually this 1&8t 12 months, especially developing thc adult SMA REACH. British Mycfrlogy socicly was face to face was ihe Translational re.searLh meeiing UK and Woilij muscle society mccling in Prague 2024. Thc muscle interest group hag mct 4 limes in total 2 fully virtually and 2 meetings face lo face (part ul BMS and standalone day in Junc 2025) for case discussions and topic led presentalion5 over ihe last 12 onihs. The RDCN (rare diseases Lollaboralive networks) accredited thc Juvenile Myasthcnia (JMG) Gravis group in 2023 and this continues to be hosted by the designated providers, Oxford specialist service, and this group lo have iTjrtllal meelings for difficult cases with JMG. GOSH has this year also been appointed as a designated ptovider. The charilies also sponsor. the muscle group'5 main annual meclillgs such a5 the British Myology society, Translational research meeting UK, Northstar and SMA REACH meetings wiihin the UK. The meetings also receive unresiricted educational grants from pharmaceutical companies. Wc work together with the Llinicians on varinug paticJ)l iDiliatives: patjCDI leatlels, e-learning modules, palieni days, children'b transition days and camps; and suppori ihe vaTiOUS neuromuscular ieams in their individual areas. such as NM networks. local educaiional meetings and lrial set ups. Page 20

British Paediatric Neurology Association Report of the Trustees ror the Year Ended 31 Mareh 2025 Lastly, we are working wilh colleagues both trainees and eonsulianls to lake a closer look at training and how we can increase opportunities and intere￿t in tr&inin¥ in Neuromuscular disorders. Last year we appoinied Dr Alison Skippen as MIG trainee representative and this year Dr Lipi Shekhar is ihe trainee rep and has already looked at initialing a dislance learning bundle on neurornuscular topics (as indicated by the trainees) and .8tartcd a tcaching group with a few other trainees and are planning to organi.sc d Ncuromuscular Study Day lor all GRID tric illee% later in the year (Autumn 2025) Fundralsing activities 6.3.8 NeuTOCUtaneous S cial Interest Grou Thili group's interest is in the clinical area of neurocutaneous.4yndromes, SULh as Neurofibromatosis, Thberous Sclerosis Covnplex and Siurge Weber Syndrome. This is d rLldlively new group with thc first term of the exec ending soon. All the exec is continuing for a sccolld term until August 2028. We are meeting twice a year which mix of vIr￿al. hybrid 2nd had an in-per.4on mccLing during Ihe BPNA conference this ycar. The neurocut2neous SIG has been sUPPOrting paediatric neurologists and paediatricians across the country with inforniation ab(iut the differcni syndromes. Menibers have been involved in supporting and giving inforniaiion lo Stakeholders and to fan]ili¢s at support days h05led by Charities. We have arranged a working group to discuss education atid are supporting a study day being set up in IA>ndon as a pilot following this discussion. As a group we are keen to discuss ai)d share infonnation aboui upcoming research and new treatmcnls. We are keen to hear from leading experts from across the UK io share knowledge and experience. 6.3.9 Trdinees, S cial Interest Grou The BPNA Trainees. Special Interest Group (SIG) is open to all BPNA trainee members and individuals interested in paediatsi¢ neurology, This includes Paedialric Neurology and Neurodisability Subspecialty Trainees ( previously GRID), SPIN Epilepsy Trainees, Paediatric Trainees, and oihers interested in Paediatric Neurology. Currently, the Trainee SIG has 110 members, To better reflecl the diverse expertise within the group, the committee has expanded ihis Ye￿ to include two Early Year Careers. Representatives- Dr Kaylita Chanliluke and Dr Laura Chapman as well as 8J) International Medical Graduate Representative, Dr Megha Raghavan . We look fonvard lo their valuable contributions. The Trainee SIG convenes twice a year- once durii)g ihe BPNA Annual Confe￿￿Ce in January and again at ihe two day BPNA Trainees Meeting in May. The 2025 May meeting will focus on Paediatrie Neur(Foncology and Neuropsychiatry, areas identified as challeng?ng to cover from the Paediatric Neurology Subspecialty Tralnee annua] Survey. The rwo day event fealuTe experl speakers, including a palient led session with a young pergon atfecleil by Functional Neurological Disorder (FND), and int¢Taciive srnall group discussions on the psychiatric assess'menl in the neurology clinic, as well as conlmunicating and managing FND. The Stuart Green Memorial Leeture will be delivered by Dr Jean-Pierre Lin, Consultdnl PaediaLric Neui'ologisl at Evelina London Children's Hospital. ThcTC will be a carers, session led by Dr Dipak Ram. Consulianl Paediktrlc Neurologist, Manchesler Hospital and CSAC Nalional Trairjing Advi50r un Consultant Applications. This year, 32 physical attendees and 18 virtual atlendees aiiended. We are very grateful ￿ all the 5pcakcrs who generously donalcd thLir Linle. R￿ordingS of these sesEions arc 4ivailable in Ihe BPNA Trainees, SIG section of thc BPNA website. Following the JaThuary meeling, members emphasisLd ihe need for regional paediatric neuTology subspe¢ialty teaching days. In respoThsc, a teaching working group was established, organising four i'irtual ￿￿h]ng days so far- covering hIS￿ry taking, examination techniques key aspects of functional onatomy in May; neuropsychiatry in Junc and neuromusclll￿ topics schedules for August and Oclober. Due to the success of thcse session5. plans are underway to adopt a centre-based approach lo enhance sustainability. Along ihe theme of teaching, two DistanLe Learning Groups focused on PacdiatriL Neuro-oncology and Ncurov&scular have run this year. Many sessions were supported by c(Trnsuliants who volunteered their time to supervise and facilitate Ihe weeldy mee(ings. Page 21

BrÉtish Paediatrie Neurology Association Report of Ihe Tr￿teeS ror the Year Ended 31 March 2025 ACHIEVEMENTS A￿'D PERFORMANCE A key role of the trainee SIG is its involvemeni with the BPNA RecruitmenE working group, which aims to improve recruitment into pacdiatric ncurulogy spccialiy training. We continue to wn annual pre-application and interview webinars for Neumlogy and Neuradisability appliunts. Thcsc wcbinars have been well-received by both appli¢anls and CSAC interviewers, wilh recordings available on ihe BPNA website in ihe careers section. Building on lasl year's initiatives we cnordiiiated the second student evenl in Lollabora(ion with the Neurology and Neuiosurgery Interebt Group (NANSIG). who have a presence acTQSS all medical school nationally. The online Saturday morning session attracted over 50 medical studenls and foundaiion dociors and received excellent feedback. Topics included 'Paihways lo Paedialric Neurology,, 'A Day in life of Paediatric Neurology Registrar and Consultant, and 'Brcaking Myths in Paediatric Neurology . Oycrall, il has bcen a successlul year for ihe BPNA Trainee SJG, marked by significant growih dnd organisalional changcs. I would like lo thank Dr Audrey Soo for her dedicated role as Chair and wish her the best as a Consultant Paediatric Neurologist. 6.3.10. UK-Childhood tnflammatoiv Dem elination This group's interest is in the clinical area of acquired inflammatory white mdtter disca5es {such as paediatric onset Multiple Sclerosis, MOGAD and AQP4 antibody driven disorders and the autoirnmune medidted encephalitides) as well as oiher less common inflammatory brain condiiions. The past 12 months has Continued to be busy . We have met every 2 mont￿8 virtually. on the 3rd Friday of every 2nd month. as a group. The meeting5 have been chaired by Paed Neurologist Cheryl Herningway with administrative support provided by the BPNA and hosted on ihe BPNA Zoom platforni. Clinical adrninistrative supp)rt has been provided by GOSH PA team. The 6 meetings have been well aiiended, with around 40- 50 individuals joining, with both national and international representaiion. The meeting forn]at has coniinued a8 before, with the fIrst hour consisting of updates and fom]al presentations, bringing everyone up io date with new treaiments and ongoing research, with the presentations recorded and made avallable on the BPNA website. The next 3 hours discussing clinical cases. We have discussed on average 10-12 clinical cases per meeting. The meeting has been excellently supported by expert neuroinflammatory colleague8 from around UK and has had expert neuroradiology from Great Orniond Street, and we thank parlicularly Dr Kshiiij Mankad and Dr Asthik Biswas for their time. The meeiings have all been expertly rninuied, copies of the minutes sent to the referrer, and a copy kepl on the GOSH EPR. A face to face meeiing hosied by Mancheqier. In May 2024 Manchester hosted ihe UKCNIDINHS England HSS (Highly Specialised Service) paediatric onsei MS meeting. Attendees included Paediatric Neurologists. trainees in neuroinflamry]ation, spcciali&t nurscs and rescaTchcTS. Ongoing projec(s, finance issues and service updates were di8cu8sed. As we go fO￿ard, inlu 2025, we will continue to meet every 2 months, with the next face to face meetlDg planned for June 2025 hosted by Oxford. 6.3.1 I. UK Neurorehabilitation S cial Tnterest Grou Dr Peia Sharples remained Chair of this group until Febtuary 2025 whcn this was handed over lo DT David Mccorniick. Duting the course of the last year three SIG meetings have been held. September 2024.. A hybrid meeting was held IT] Glasgow immedialely preceding the International Paediatric Brain Injury Society {IPBIS) meeting. There were a number of academic preseniati(Ins at thi.q meeting including- Paediatric TBI and Youth Offending.. Risk facior or misnomer? (Professor Liam Dorris) Vitamin D levels and body composition in children completing thc ncurorchabilitation pathway at King's College Hospital (Dr David Mccormick) - Occupational therapy and e￿lY therapy for ABI in PICU (Mr Ethan Rebert) Page 22

Brllish PaedSalrie Neurology Association Report of the Trustees for the Year Ended 31 March 2025 ACHIEITMENTS AND PERFORMANCE FebTuary 2025.. This was my fjrst meeting as Chair and Dr Anurag Saxena took over as secretary from Dr Jane Williams. Ai this virtual meeting: We had feedback from Mr Anthony Prndhoe of NHS England on the paedialric neurorehabiliution service 5pecificalion Teview and Ihe ongoing nalional survey of Ihese serviLes. Mr Prudhoe described a range ol models in place de￿&& ihe counlry with buth different comtnissioning and pathway m()dels. Whilsl he acknowledged that minimum Siandards were necessary. there WAS no one model emerging, and he communicated that there were no new funds lorihcorning from the NHS with regard io paediatric neuTorchabilitaiion services. He undenook an extcndcd question and answer scssion with rnembers from unit5 around the UK, with a covnrnon theme becoming clear of practitioner5 having diffIculty engaging commissioners in discussions about fijture developmenr of services. It was acknowlcdgcd that Ihc Id¢k of dcsignatcd bcds for pacdiatric ncurorehabilitalion paticnts in many ccntres were adversely affecting the ability to implement good care. Mr Pwdhoe advised that the national survey was ongoing and thai he would Tepon back io the SIG. Dr Anurag Saxena discussed data from the BPNA WOTkfor¢e d9￿Ments and the draught service specifJ¢ation for paediatric neurorehabilitalion. He noled ihal rnost paedialric neurorehabiliTation cenlres are co-located with the regionoj paediatric neuroscience cenlres and Ihat whilst there was bioad geographical representalion of these centres in the UK there was lengthy travel for sorne families to their nearest unii. I led discussions on Ihe stThclure of Ihe special inleresl group going forward. and a decision was made to have represenwion from most disciplines involved in paediatric neurorehabilitation on a cor¢h¥orking group for the SIG to include.. physiotherapy, occupalional Iherapy, speech and language therapy, neuropsychology, specialist nursing, and voluntary sector representation. It was agreed that Dr Pela Sharples would transition to the research lead and Dr Jane Williams to ihe transition lead for ihe SIG. The suggestion was tha¢ SIG members put themselves forward for Ihese posls in the coming weeks. June 2025: A third SIG meeting was held on 27th June as another virtual meeting. This was intended to follow a second feedback session on the national survey of paediatric neurorehabililation services by Anthony Prudhoe, bul he hdd to cancel this meeting al the last minute due lo oiher demands. He made clear in correspondence that there is still a process of needing to report this survey and make recommendations to NHS England by the 24th .September 2025, and committed to presenting these findings in a separate meeting in the not too distant ￿tllre. Other matters addressed at Ihis meeting.. Now that she has left clinical practice, Dr Jane Williams is stepping down transition lead and Dr Denise Cr07ier was nominaled and approved in ihis role. number of names were put forward for other new roles in the corelworking group (as olltlined in the February meeiing}, with essentially all filled, aT]d following discussion additional rDle8 of a representative spinal cord injury link worker and a representative from both Childrcn's Brain Injury Trust and Back Up w¢r¢ agreed. Dr Peta Sharples presented on a protK)s¢d ￿searCh prograrnrne. She has Secured NIHR fuTJding for a 3Y2 yeaT PhD studeniship looking ai modelling for prognosti¢ation following acquired brain injury using a standardised set of assessrnenl tool$. This follows on from work discussed in a meeting held in November 2023 with SIG members. The proposal is thai a limited number of assessmeni tools of Lhildren and young people with ABI ¢we agreed and implemented on a weekly basis, thai there is ceniral daia collection over a two year period, and that ihis daL2 is then used for developing a model boih to prognosticate following ABI and to infonn therapeuiic interventions. The SIG were very much in support of this proposal and awaii mulii-eenlre eihics approval in this regard in addiiion io the ouicomes of the planned July 16th meeting seiting ihe agreed assessmeni tool portfolio. Page 23

British Paediatri¢ Nevrology Assoclation Report of the Tru$lees for the Y￿r Ended 31 Mareh 2025 ACHIEVEMENTS AND PERFORMANCE Furiher discussions were held regurding the SIG meeting programme on an annual basis. It was Tatifie4J that we would have NTO Virtual rneetings per year and one hybrid rneeting. inclusive of both face to face and virtual attendees. and thai tbis meeling would be a tsll day academic meeting. This is now proposed for October or November 2025. site yel to be dclcrn)ineJ. A number of potenlial topics were discussed for this meeting includAng.' family sysiemic grier following brain injuries lo children: persisleni disorders of consciousness and interventions for the8e' aetiologies of aLquired brdin injuTy and their implications lor lleurorehabilitaiion programmes, especiailv stroke; posl-traumalic amnesia and its managelnent. A p￿¥[amInC will be woiked up ovei the LoJning months and third party sponsorship sought in order to support the conference io avoid significant cost to attendets. Overall, the last 12 months has bccn a succcssful PCTiI)d for thc pacdiatric ncurorchabilitaiion SIG with a succcssful transition to new leadership and effective rneetings joined by enihusiastic participants. There has been a broadening of reprcscntation in SIG kcy rolcs, not only from mcdical collcagucs but also allicd hcalth pmlcssionals and other discipline8 workimg in the field, and we have exciting plans going forward both for comiT]g acadcrnic meetings and UK wide research projects. 7. Clinical Governance BPNA has been consulied by NHS NICE to comment on guidelines and quality Standards and by NHS England to commeni on the new i]rug treatments. If you would like more infonnats.on about which of Ihese the BPNA have contributed please contact the Director. Internal and external factors Risk mana emenl The lrnsfees have assessed the major strategic, business, and operational risks lo which the Associaiion is exposed and are satisfied th￿ systems and procedures in place lo monitor and eonlrol those risks lo mitigate any impaci Ihey might have on the Association. A risk register is maintained and updated regularly. Princi al risks and uncerlainlics We have currently identified the following factors as being the main risks to the BPNA.. Pressure from NHS T￿StS on BPNA members lo increase the number of clinics/palienlS and limii other activities. This has the potential to impact on the voluntary Èime given by BPNA members to lecture, tutor and mentor at short-eourses, distance-learning, And menioiing. Our consuliani members have remained robusi and enihusiaslic in this support, and we hope that this will remain the ease, bui il is clear thai ihe BPNA would be unable lo contsnue in delivering education without this generously donated time. Thi5 is being moDiiored by Educatioii, Quality & Standards committee and Professional Support Committee with the aivn to Start a faculty retention working group this year lo resear¢b and review the risks. Reputation in being associated with unpmfc5sional or uneihical or even CTiminai activilies in tbe UKlabrodd due to disengdgeTncnt about hol topic issues. This can bc highlightcd in IcLcnt ycats OTI LI￿n￿bi5-bdSed mcdicinal pri)ducts (CBMPS) and Paedialric Acute-onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmunc NcurupsyLhialriL DisurdcTS AsSOLiatcd wilh SireploLoLcal Inleciions (PANDAS}.The BPNA ha workcd haTd in cngaging wilh such issucs and producing thcir own or cvllaboraiion with oiher prolessivnal colleges to Pf(Mluce working statements.Similar issues will no doubt arise in the future and the BPNA musi engage wilh those groups to be seen as professional and supportive while not pulting more pressure on the BPNA members and wider medical professionals in the paedialric neurology communily. FINANCIAI. RFVIEW Finaneial position The balance sheet position shows nel current assets of £907.436 (2024 - £942,510). resulting from a dccrca5c in the cash at bank to £l,(K12,347 {2024 _ £1,053,.537). This has been accompanied by an increase in debtors to £1 10,040 {2024- £65,203), and decrea.se in creditors lo £205,890 {2024 - £185,253). Page 24

British Paedigtric Neurology Assoclation Report of the Trustees for the Year Ended 31 March 2025 At Ihe year end the chariiy has unreslricied freely available CU￿ent reserves of £866,101 (2024 £764,459) which excludes tangible fixed assets of £20,083 (2024 - £21,243). Given the charity's current levels of expenditure this would allow for approxiinately just over seven months (2024 seven moiiths) of trading wiihout further freely available reserves becoming available. Prinelple funding sources The BPNA raises funds rnainly through payments received for ils educational aciivities, which include short-courses. annual conference, onltne distance-learning course; membershlp subscriptions; and sponsorship. We have also raised money Ihrough the voluniary contributions of members. Total incoming re,wurces for the y&ir have increased to £1,278,107 (2024 - £1,227,881). This increase has arisen mainly from the Increase in short course sponsorship lo £40,250 {2024 - £14.750) and the increase in UCB sponsorship 10 £15,000 {2024- £nil). Donations and legacies have decreased in Ihe year lo £359,015 (2024 £411,123. Sponsors of its annual conferenLe symposiums generaiing funds of £66,1)IKI (2024 - £66.000), and generating annual conference sponsorship income of £128,130 (2024 - £110,-S(Kl). See "Note 4 Donaiions and Legacies" and "Noie 6 Income from Charitable Aciivities" within the notes lo (he financial sthtements for a deiailed breakdown of income received in the year. Investment policy and objectives The policy of the BPNA is lo invest ils reserves in the fullher development of its charitable aims. The BPNA has also committed reserves to the sustainability and further development of both the distance learning and short courses. As a result of receni financial perforniance, derived from additional incoming resources, the curreni level of reserves the BPNA holds as cash balances amounting lo £1,002,347 (2024 - £1,053,537} and is exploring invesimenl opportunities for the reserves. Any in￿re$l eamed will be uiilised for research projects and oiher dciivitie.s in line with Ihe BPNA charitable objectives. It has been agreed that the BPNA Website and brand needs investhieni and a certain percentage of the BPNA reserves will be invested inlo the development of the Websile updale projeci. Reserves policy The totsl ￿nds held at the year end were £921,.f24 (2024 - £963.753) and of which £35,340 (2024 £178,051) is maintained within restricted funds for their delatled purposes as described in the notes lo the financial sla(ements. Further delails of reslricted funds are included within the noles lo the financial slaternents. The BPNA imi)lemented two extenial VAT reviews due io our large income and making sure we are complianl with HMRC. It was confirn]ed Ihal we should have been historically VAT regisiered. The BPNA are now VAT registered and the charity was able to recoup historical VAT since l January 2018 from companies that should have been invoiced VAT. With ihat, it is still to be confirnied the penalty the BPNA need io pay to HMRC. It should noi be any more than £6,0(M) from the latest letter r￿e1Ved by HMRC. This means there will be no loss incurred by the BPNA for the historical VAT needed io be paid io HMRC and whai was recouped back from Lompanies. Overall, Ihe financial position of ihe charity remains healihy, though the trusiees coniinue to pay close atteniion to the mix of aclivilies in order lo ensure that in trying to achieve ils objectives il does not lead lo delerioraiion An the financial sthbility of the charity or sthff bum out. A subslantial proportion of the reseryes in the balance sheet are represented by the cash at bank and in hand tolalling £1,002,347 (2024 - £1,053.537) in order lo facilitate Ihe continued aclivities of Ihe charity by holding highly liquid assets. The trustees regularly review the finances, budgets. and cash flows 10 aid eff¢¢tiv¢ stewardship of the charity. Page 25

BritRsh Paediatrie Neurology Association Report of the Trustees for the Year Ended 31 March 2025 FINANCIAL REVIEW Thc trustees reeognise that the level of reserves fluctuates during peri(Mls of investment by the charity and ensure an adequate reserve is maintained. To this end, in 2023-24 the trusiees increased an unrestr1c￿d contingency fund io £250,000 which is held in OTder to mitigate Ihe risk of liquidily concerns. The Iruslees have agreed thc level of funds hcld in this account based on the equivalent of flve month's Secretariat salaries plus major overheads including office rentals. This policy As reviewed every 12-months. Funds in deficit PETI International update had a deficit as at the fmancial reporting dale or ihe comparative fmancial reporting dalc. FtrruRF. PI.ANS During 2025-26 recrnitment lo paedialric neurology will conlinuc bul Irainec placcs havc bccn fillcd Io LapaLity in recent years. Relationships with othcr a550ciaLioTJS and collcgcs will continuc to dcvclop (RCPCH & Association Df British Neurologists). The BPNA Strategy day happened in September 2024 in line with the Jjew BPNA President taking up their position which will inlonn the direction the BPNA should go operationally and the final docuTneTJt should be produced by the end of the 2025126 year. PETI will be launched in Singapore in 2025 wilh plans to launch in both the Caribbean and Mexico soon afierwards. The Acute and ACT courses will undergo a revision in June and September 2025. STRUCTURE, GOVERNANCE AND MANAGEMENT Governlng document The BPNA is governed by its COIISlitution. llpproved at an ¢xtr&ordinary general meeting on 3 December 2014 and updated xl the Annual Genernl Meeting h¢ld on 23 January 2019. Meth(K] of appointment of trustees The managemeDt of the Association 1$ the re$ponsibility of the trusiees who are elected by BPNA members and appointed under the ternis of the Constitution. When a new Trustee 15 appointed a procedure is followed under BPNA policies which includes Trustee eligibility declaration, scnding a copy of 'The Essential Trustee. guide, Conflicts of Interest policy and Declaratiim of inrerest form. Thcy arc also vlfcTC41 trainiT]g. Organisational structure and decisiun-making The Iru5tces n]cci fouT times per year (usually January, June, September, NoveTnbeT) when moTe in depth slralegic decisions and busAness matters are discussed. Monihly Zoom m¢elings are also held. Council is a larger body that meets twice per year (January and MaylJunelJuly). During 2018-19. Council was expanded to include represeniation from every UK paediatric neurology tertiary centre and the Chairs of the special interesi groups together with the representhtives co-opied from Telaied organisaiions. The purpose of Council is to ensure a good exchange of information and idea5 related to the care of children and young people N'iih neurological condiiions and paediairic neurology education and training between Centres and other key organisations. Please see list of BPNA Council members below.. Page 26

British Paediatric Neurology Association Report of the Trustees ror the Year Ended 31 March 2025 STRUCTURE, GOVERNANCE AND MANAGEMENT Members of BPNA Council Serving During 202&25 Executive Name President Dr Ailsa McLellan Secretary Dr Daniel Lumsden Chalr, Research Dr Satn Amin Chair, Educaiion Quality & Siandards Dr M2nali Chitre Chair, International Educalion Dr Jane Hassell Executive Director, BPNA Mr Philip Levine Treasurer Dr Santosh Mordekar Professional Support Officer Dr Manish Prasad National Training Advisor Dr Dipak Ram Tenn Ex ires January 2027 January 2028 Janukuy 2028 JanU￿Y 2027 January 2028 January 2026 JaDuary 2026 January 2027 Paediatric Neurolo Aberdeen Belfasi Birmingham Bristol Cambridge Cardiff Dundee Edinburgh Glasgow Leeds Leicesler Liverpool Manehester New¢astle-upon-Tyne Nottingham Oxford Presion Sheffield Southampton London.. Great Onnand Sii'eei Hospiial London.. Chelsea & Westminster Hospital London.. St Mary's Hospii London: The Royal London London: Eveh'na London ChAldrei)'s Hospitsl London.. Si George's Hospital Cenlres resenlative Dr Elma Siephen Dr Sandya Tirupathi Dr Annapurna Sudarsanam Dr Andrew Mallick Dr Deepa KrAshnaknmar Dr Johann le Water Ndude Dr Alice Jollands Dr Krishnaraya KamathTallur Dr Sarah Abernethy Dr Lydia Green Dr Nahin Hussain Dr Rajesh Karuvattil Dr Siobhan West Dr Auna Basu Dr Singaravadivelu Velmuwgan Dr Nadine Mccrea Dr Christian De Goede Dr Min Tsui Ong Dr Jaspal Singh Dr Jane Hassell Dr Naila lsmayilova Dr Sushil Beri Dr Mlchael Yoong Dr Daniel Lumsden Dr Luigi D'Argenzio ear terni January 2027 January 2028 January 2027 January 2027 January 2026 January 2026 January 2026 January 2028 January 2026 January 2026 Jaiiuary 2026 JaThui￿ 2027 January 2026 January 2027 January 2027 January 2028 January 2026 January 2028 January 2028 January 2028 January 2028 Co-opted January 2028 January 2028 January 2028 cial Inierest Grou British Paedialric Epilepsy Group Cerebrovascular Children's Headache Network Chair Dr Suresh Pujar Dr Jaspal Singh Dr Michael Taylor Dr Anthony Hart (Co-chair 2nd Temi) Dr Brigitte Vollmer {Co-Chair) Dr Lydia Green Dr Ram Kumar Dr Tracey Willis (2nd Term) Dr David Mccormick Dr Cheryl Hemmingway Dr Sam Amin {Co-Chair) Dr s￿ah Ayleit (Co-Chair} Dr Manali Chitre (Chair) ear tern] June 2025 February 2026 January 2028 Fetal & Neonatal Neurology Fetal & Neonatal Neurology The Genetic White Maiter Disorders British Paediatric Movement Disorders Musclc Inieresl Group UK Neurorehabilitalion UK-Cbildhood Neuro-lnflammatory Disorderq Neurocuianeous Neurocutaneous RCPCH SPIN Epilepsy Trainees May 2025 May 2025 Suly 2027 May 2028 May 2025 January 2027 May 2025 August 2025 August 2025 August 2025 Page 27

British Paedialric Neurology Associalion Report of the Trustees for the Year Ended 31 March 2025 STRUCTURE, GOVERNANCE AND MANAGEMENT Trainees, Chair Trainccs, Depury Chair Dr Audrey Soo Dr Abigail Lazenbury June 2026 June 2026 CO-O tcd Editor. DMCN British Paediatric Neurosurgical Group Chair, Neurodisability CSAC & BACD Rep Paediatric NeuToscienses CRG Neuropsychialry Representative Short c.ourse Development Manager Lead of Distance Learning Lead for Inennalional Programme Development and Evaluation rcscnlalive Dr BcrnaTd Dan Dr Pasquale Gallo Dr Jill Cadwgan Dr Anila Devlin Dr Ashley Liew Dr Colin Dunkley Dr Louise Hartley C(Fopted Co-opted Cu-opled Co-opted Co-opted Co-opted Co-opted Prof Martin Kirkpatrick Prof Andreas BNnklaus& Dr Joseph Symonds Dr RiCh￿d Davenport To be confirmed Co-opted BPNA 2026 Glasgow Organiser Presideni, Association of British Neurologisis Trainee Rep, Neurodisability January 2026 Co-opted January 2027 Key management remuneration Toial remuneration paid to key managemeni personnel during the f￿anCIal Ye￿ Included wages and salaries amounting to £72,885 (2022- £85,853) and contrÉbulions lo defined contribution pension schemes of £3,338 (2022 - £3,907). Pav and remuneraiion of Lev mana ement rsonnel Perniancnt staff have yearly appraisals with aims to achieve for the year and are given opportunities lo develop themselves with training ihal the BPNA covers ihe cost towards. If staff achieve all iheir objectives they will gel a grade increase {between 2% & 4%) until ihey reach the top band of their pay grade. BPNA staff positions and pay are reviewed annually and are benchmarked within the recruilment markei and similar organisations. REFERENCE AND ADMINISTRATIVE DETAILS Registered Charity number 1159115 Prineipal address BPNA Education and Accounis Office Suitc M2 Atria Spa Road Bo1￿￿ BLI 4AG Truslees Dr A McLellan DrDRam Dr S Amin Dr D Lumsden Dr M Prasad Dr S Mordekar Dr M Chitre Dr J Hassell (appOin￿d 9 January 2025) Protessor M Kirkpairick (stepped down 9 January 2025) Page 28

British Paedlatrlc Neurology Assocftatlon Report of the Trustees for the Year Ended 31 Mareh 2025 REFERENCE AND ADMINISTRATIVE DETAILS Auditor Donnelly Bentley Ltd 70 Chorley New Road Bolion BLI 4BY Bankers BarLlays Bank PLC 15 Bene'i Streer Can]bridge CB2 3PZ TRUSTEES, RbSPONSIBILITY STA TEMENT The irustees are responsible for preparing the Report of the Trustees and (he financial slalements in accordance with applicable law and United Kingdom AccouJ)ting Standards (Uniied Kingdom Generally Accepted Accounting Practice) including Financial Reporting StandaTd L02 "The Finan¢ial Reporting Standard applicable in the UK and Republic of Ireland" Charity law requires the trustees lo prepare financial slatements for ¢a¢h financial year, Under that law, the irustees have elecied lo prepare the financial statements in accordance with Unit¢d Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Siandards and applicable law). Under charity law the trustees must not approve the financial statements unless they are satisfied thai ihey give a true and fair view of the slate of affairs of the charily and of the incoming resources and application of resources, including rhe income and expendilure, of the Ch￿71Y for Ihat period. In prepating those fjnancial statemen18, Ihe In]stees are required to seleci suithble accounting policies and then apply them consisienily; obserye the methods and principle.8 in the Charities SORP. make judgements and estima*s that are reasonable and prudent; ststc whether applicable accounting standards have been followed, subject to any rnaterial depamires disc105ed and explained in the fjnancial statcmenls; prepare the financial statements on the going concen) basis unlc55 It is inappiuprialc lo presume thal thc chatily will conlinue in busines5. The trustees aTe responsible for keeping proper accounting iecords which disclu&e with reasonable accuracy at any lime the financial position of the charity and to enable them to ensure that the financial siatements comply wilh the Chariiles Act 2011 and Thc Charity {AccouJ]ts aDd Reporls) Regulations 2008. They also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 4 December 2025 Approved by order of the board of Iru5tees on ................. ...... .... - and signed on ils behalf by.. Dr S Mordekar- Trustee Page 29

Reporl of the Independent Auditor to the TThstees of British Paediatric Neurology Association Opinion We have audited the financial staiemenls of Brilish PaediatTiC Neurology Association (the 'charity') for the year ended 31 March 2025 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Siaiemenl and notes lo the tIn￿cIal slatcrnenls, including a summary of significant accounting policies,. The finanLial reporting framework that ha8 been applied in thcir prcpardlion is dpplicable law and United Kingdom Accounting Standards {United Kingdom Generally Accepted Accounting Practice). including Financial Reporting Standard 102 The Financial Reporting Standard applicablc in ihc UK Republic of Ireland,. In our opinion Ibe financial slatemeDts'. give a true and fair view of the state of the ch￿ty'S affairs as ai 31 M￿ch 2025 and of it% incoming resources and application of resources, for the year then ended. have been properly prepared in accordance with Uniied Kingdom Generally Accepted Accounting Practice. including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland,; and havc bccn prepoJed in accordance with the requirements of the Charities Aci 2011. Basis for opinion We conducted our audit in accordance wilh International Siandards on Audiiing (UK) {ISA8 (UK)) and applicable law. (h]r respoi)sibilities under ihose siandord5 aTe further described in the Auditor responsibilities for the audit of the rinancial St8￿Ments section of our repon. We are independent of the charity in accordance with the ethical requirements ihat are relevani to our audii of the financial slalements in the UK, including the FRC'S Ethical Siandard, and we have fulfilled our oiher ethical responsibilities in accordance with these requirements. We believe that the audil evidence we have obtained is sufficlent and appropriate lo provide a basi.$ for our opinion. Concluslons relating to going concern In auditing Ihe financial slalements, we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the fmaT)cial statemenls is appropriate. Based on Ihe work we have perfornled, we have not identified any material uncertainties relating lo evenls or conditions Ihat, individually or colleciively, may casl significant doubt on the ¢hariry'S ability to continue as a going concern for a period of at least twelve months frorn when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the lrnslees with r¢spect to going concern are described in the relevant sections of this report. Other Inforniation The truslees aTe respunsible for Ihe oiher infO￿all0n. The other information comprises The infnrniation included in the Annual Report. other than the financia] sthiernents and our Report of the tndcpcndcn( Auditor Ihereon. Our opinion on the financial sthtements does not cover the other information and, except lo the extent otherwise explicitly sthted in our report, we do not express any lonn of assurance conclusion thereoD. In conncction with our audit of the financial statements, our responsibiliry is to read the other inforniation and, in doing so, consider whether the nther information is matcrially inconsislenl with the financial .statementS OT our knowledge obiaincd in the audit or othenvise appears to be materially mis5lalcd. ￿ we identify such material inconsislencies or apparent material misstalements, we are required to deterniine whether this gives rise to a rnaterial mi55talernent in the financial statements thern.%elveb. Il, bab¢d on ihe work we have performed, we conclude thai thcre is a maleTiai misstatement of this other inforrnatioT), we are required to report that fact. We have nothing to repon in ihis regard. Matters on which we are requlred to report by exeeption We have nothing to report in rc5pect of the followin8 matters where the Charities (Arcounts and Reports) Regulations 2008 requires us to report to you if, in our opirjion: the inforniation given in the Report of the Trustees is inconsistent in any material respect with ihe financial statements- or sufficienr accounting records have not been kept. or the financial slaiemenis are not in agreement with the accounting Tecords and returns; or we have not received all the information and explanatiOIIS IATe require for our audit. Page 30

Report of the Independent Auditor to the Trustees of British Paedialric Neurology Association Responsibilities of Iruslees As explained more fully in the Trnslees, Responsibilities Ststemeni the tnjstees are responsible for the preparation of the financial slatemenis which give a true and fair view, and for such iniernal control as the lrnstees determine is Decessary io enable the preparaiion of flnancial sta￿ments thal are free from material mi5Statemenl, whetheT due lo fraud or error. In preparing the financial siaiemen(s. the trnstees are responsible for assessing the charily's ability to continue ds a going concern, disclosin¥, as applicable, tndllers related to going concern and using the going Loncern basi.8 of accounting unless the tru.stees either intend to liquidate the LhaTity 01 lo cease operations. or have Do Tealistic alternative bul lo do so. OUT reswbnsibilities fi>r the audit of the financial statements We have been appointed as auditor under Section 144 of the Chartties Act 2011 and report in accordance with the Act and relevani regulatinns made or having effect thereundcr. OUT objectives are lo obtain reasonable assurance about whether the financial Sta￿rnents as a whole are free from rnaterial misstatement, whether due to fraud or err(>r, and to Issuc a Rcporl of Ihe Independeni Auditor that includes our opinion. Reasonable asqurance is a high level of a8surance, but 15 nol a guarantee Ihal an audit conducled in accordance wilh ISAS (UK) will always detecl a material n]isstatement when li exisES. MissiatemenLs can arise fri)m fraud or error and are considered material if. individually or in the aggregaie, they could reasonably be expected to influence the economic decisions of users taken on the basis of these fiTJancial statements. The extent to which our Procedures are capable of de￿cting iTregularilies. including fraud is deiailed below.. I￿egularitIcs, including fraud, are inslance5 of non-compliance with laws and regulations. We design procedures in line with our responsibilities, oudined above, to detect material misslalements in respeci of iffegularities, including fraud. The extent lo which our procedures are capable of detecting irregularities, including fraud is deidiled below.. We obtained an understanding of the legal and regulatory framework applicable to the ch￿￿tY and the secior in which li operaies and considered the risk of non - ¢omplian¢e wilh applicable laws or regulations. We deiern]ined that the following laws and regulations were most signifJ¢ani.' Ihe Charities Aci 2011 and Accounting and Reporting by Charities.. Statement of Recommended Practice applicable lo ehdrities prepgsing their accounts in accordance with the Financtal Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019. We designed audit procedures lo respond lo Ihe risk, recognizing that the risk of not dete￿Ing a material misstatement due io fraud is higher than the risk of not detecling one resulting from error, as Iraud may involve deliberate concealment, for example, forgery or inlentional misrepresenlations, or through collusion We obiained an understanding of how the charity is complying with those Icgal and regulatory frameworks by rnaking enquirics of the MI￿age1nenI. We corroboTated our enquiries through our review of boaid minuies. Our tests also included agreeing the tinancial statcmcnts disclvsurcs to underlying supporting documentation. There are inbcTcnt limitations in the audit pr()cedures described abovc aTJd, Ihc furthci Temoved non-compliance with laws and rcgulaiions is from the events and transactions reflected in ihe finxnclal statements: the less likely wc would becorne awate of it. We did not identify any kcy audit maltcrs Tclaling to irregularities. including frnud. We also addressed the risk of management override of iniernal controls, including testin¥ journals and evalualing whether there Wds cvidcncc of bias by the lrnstees thal represented a risk of material misstatement duc io fraud. A further description (yf our responsibilities for the audit of the financial statements is located on the Financial Reporting Council'5 wcb5ilc ai www.frc.org.uklaudiiorsresponsibiliti&4. This de8cription fonns parl of our Rcport of the Jndependcnt Auditor. Page 31

Report of the Independent Auditor to the Thisttts of Brilish Paediatric Neurology Association Use of our report This report is made solely to the charity's i￿SteeS, as a body, in accordance with Part 4 of the Charities (A¢¢ounts and Reporty) Regulationy 21)08. Our audit work hds bccn undcriakcn so thal we might state to the charity s Iruslees Ihose matlers we are required to state to them in an audiior's repon and for no other purpose. To the fullest exlent perniilted by law, we do not ¢iccepl or dssume responsibilily to aJ)yonc othcr than the ch¢fity and the ¢harity's trustees as a body, for our audit work. for this report. or for the opinions we have fornied. D,.4kn* L¥d DonnellyBentley Ltd 70 Chorley New Road Bolton BLI 4BY DonnellyBeudey Ltd is eligible for appointment as auditor of the charity by virtue of its eligibility for appoinlment as dudilOI of a company under seclion 1212 of the Companies Act 2006. Page 32

British Paediatric Neurology Association Slalement of Financial ACti￿tieS for the Year Ended 31 March 2025 2025 Total funds 2024 Total funds Unresiricted funds Restricted funds Notes INCOME AND ENDOWIMENTS FROM Donations and lega¢ies 183,582 175,433 359,015 411.123 Charitable activities Annual conference Short courses Disiance learning courses Iniernaiional short courses Research Membership and profes.sional support Conferen¢es, courses and recharges Professional support Support cosis 313.678 380.843 63.155 16,151 720 121.910 313,678 380,843 63,155 16,151 720 121,91LI 294,950 288,591 67,281 3,469 1,200 117,784 11,670 5,499 6,641 6,641 1.200 1,200 3.810 Invesiment income 14,794 14.794 12.388 Total 1,102,674 175,433 1278.107 1.217,765 EXPENDITURE ON Charitable activities Annual conference Short courses Distance learning courses International short courses Research Membership and professional suppori Support costs Govemance costs Invlted Reviews 284.531 341.010 50,112 122.476 62,354 134,365 (78,571) 85,223 691 284,531 341,010 50,112 327,109 62,354 134,365 34,941 85,223 691 338.310 260.287 96,972 184,219 105,449 135,500 11,224 43,918 10,771 204,633 113,512 Total 1,002,191 318,145 1,320,336 1.186,650 NET INCOMEI{EXPENDITURE) 100,483 (142,712) (42,229) 31,115 RECONCILIATION OF FLNDS Total funds brought fonvard 785,702 178,051 963,753 932,638 TOTAL FUNDS CARRIED FORWARD 886.185 921,524 963,753 The nates form part of these financial slalements Page 33

British Paedlatrle Neurology Assoclatlon Slatement of Financial Activities for the Year Ended 31 March 2025 CONTINUINC. OPERATIONS All income and expenditure has arisen from ¢ontiDuing activliies. RESTRICTED INCOME AND EXPENDITURE Comparative5 for income and expendilure All income and expenditure in 2024 was unrestricted apart from.. Donatfions and legacies income Iniernational tkague Against Epilepsy (ILAE) THET grant GW l Jazz Pharma 78.282 159,502 23.338 Charl¢able activities expenditure Short COUTses 111.320 The notes form part of these financial slarements Page 34

BrAtAsh Paediatric Neurology As50cialion Balance Sheet 31 March 2025 2025 Total funds 2024 Tolal funds Unrestricted funds Restricted funds Noies FIXED ASSETS Tangible assets 12 20,083 20,083 21.243 CURRENT ASSETS Siocks Debiors Cash at bank and in hand 13 14 939 110,040 967,007 939 110.040 1,002,347 9,023 65.203 1,053,537 35,340 1,077,986 35,340 1,113,326 1,127,763 CREDITORS Amounts falling due within one year 15 (205,890) {205,890) {185.253) ET CURRENT ASSETS 872,096 35.340 907.436 942.510 TOTAL ASSETS LESS CURRENT LIABILITIES 892.179 35,340 927,519 963,753 PROVISIONS FOR LIABILITIES 17 (5,995) (5.995) IYET ASSETS 886.184 35.340 921,524 963,753 FUNDS Unreslricted funds Restricted funds 18 886,184 35,340 785,702 178 051 TOTAL Fu￿Ds 921524 963,753 The finan¢ial stat¢ments were approved by the Board of TNs¢ees and authorised for issue on 4 December 2025 and were signed on ils behalf by: Dr S Mordekar- Trustee The noles form part of these financial statements Page 35

British Paedialric Neurology Association Cash Flow Ststement for the Year Ended 31 Mareh 2025 2025 2024 Notes Cash flows from operating activities Cash generated from operations Provision (64,971) 5,995 78,588 Ncl cash (used in)Iprovided by operating activities (58,976) 78,588 Cash nows from investing actiiryties Purchase of tangible fixed assets Sale of iangible fixed assets Interest received (7,591) 583 14.794 {18,610) 36 12,388 Nel cash provided by/(used in) investing aclivilies 7,786 6,186) Change in cash and cash equivalents in the reporting period Cash and cash equivalents at the beginning of the reporting period (51,190) 72,402 1,053.537 981,135 Cash and Cash equlvalent$ at the end of the repoTtinE period I.IK)2,347 1,053.537 The notes forni part of these financial slalements Page 36

British Paediatric Neurology Association Notes to the Cash Flow StatemenÉ for the Year Ended 31 March 2025 RECONCILIATION OF NET IEXPENDJTURE)IINCOME TO NET CASH FLOW FROM OPFRA TING ACTIVITIFS 2025 2024 Net (expenditure)lincome for Ihe reporting period (as per Ihe ststement of Financial Actiiuties) Adjustments lor: Depreciation charges Loss on disposal of fixed assets Interest received Decrease in srocks Increase in debtors Incre&se in creditors (42,229) 31,115 6.696 1,472 (14,794) 8,084 (44,837) 20,637 7,081 652 {12,388) 2,038 (25,152) 75,242 Net eash {used ID)Iprovlded by operxtfitsns 64,971) 78,588 ANALYSIS OF CHANGES IN NET FUNDS Ai 114124 Cash flow At 3113125 Net cash Cash al bank Lmd in hand 1,053,537 (51,190} I,(X12,347 1,053,537 (51,190) 1,002,347 Total 1,053,537 1,002,347 The notes forrn part of these financial stateTnent5 Page 37

British Paediatric Neurology Association Notes lo the Financial SlalementS for the Year Ended.11 March 2025 STA TirroRY INFORK4TION British Paedialric Neurology Associ#tion is d charitable incoryorated organisation regislered with the Charity Commission for England and Wales. The registered charity number number is 1159115 and the principaI address is 2 Si Andrews Place, Regents Park, London, NWI 4LB. The charitable incorporaied organisation constin]ies a public benefit entity as defined by FRS 102. The presentation cU￿encY of ihe financial statements is the Pound Sterling (£). ACCOUNTING POLICIES Basis of preparing the fjnancial ststements The financial statements of. the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities.. Staternent of Reciimmended Practice applicable tn charities preparing their accounts in accordance with the Financial Reporting Standard applicable in ihe UK and Republic of Ireland (FRS 1021 (effective l January 2019),. Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland, and the c.harities Act 2011. The financial statements have been prepared under ihe historical cost coni'ention. Going concern The Trustees have assessed wheiher tbe use of the going concern basis is appropriate and have considered possible events or conditions that might cast significani doubt on the ability of the charity to continue as a going concern. The trnstees have made this assessmeni for a period of al least one year from the dale of approval of the financial sialemenis. In particular Ihe irusiees have considered the ch￿IlleS forecasts and projeclions and have taken account of pressures on income. After making enquiries the trustees have concluded that there 15 a reasonable expectatioii that the charity has adequaTr resources to continue in operational existence for the foreseeable future. As such the charity can expect to be able to meet Its liabilities as they fall due in the period of ai least 12 months from the dale of approval of Ihese accounts. However. there can be no certainty in relation to these matters. On this basis the Trustees have concluded that the charity is a going concern. The financial statements do not include any adjuslments ilial would result from the charily not being able to meet its liabilities as they fall due. Income All incoine is recognised in the Siaiement of Financial Activities once ihe charity has entideiDent to the funds, it is probable thai the income will be received and Ihe amount can be measured reliably. Income from grAnL$ 2nd donatlans Donations and grants are recogThised when they have been communicated and received in writing with notification of both the amount and settlement date. In the cvent that a donatiun ur grant is subjcct tu conditions that require a level of perfomiance before the charity is entitled to the funds, the income is deferred and not recoEnised until either those conditions are fully met, or the fulfilinent of ihose condiiions is wholly wiihln ihe control of the chaTity and it i& probable thal those conditions will be fulfllled in (he reporllng peri(Kl. Income from membership subscriptions McmbLrship subscriplions inilidlly reLogDised in the period that the member pays the subscription lo the chatily. Membership subscriptions received in the year relating to the period after the reporling dale are recognised as deferred income. Ineome from sponsorship agreements Sponsorship incorne is initially recognised when invoiced in line with the terms of (he sponsoTship agreemenl. Income received or invoiced in the year relating to the period after the reporting date are recognised as deferred income. Page 38 continued...

British Paediatric Neurology Association Notes to the Financial Statements . continued for the Year Ended 31 March 2025 AccOUNT￿G POLICIES - Continued Income ID¢ome from conferences Income in relation to conferences is initially recognised in the period in which ihe aiiendee pays rhe a(lendance fee. Inconie received for conferences taking place after the reporting dale are recognised as deferred income. Income from courses Income in relation to courses is initially recognised at the point which the attendee has booked and paid for their attendance on the course. Income re£eived for courses iaking place after the reporting date are recognised as deferred income. Income from EPNS reeharges Income in relation lo EPNS recharges is initially recogni5ed al the point which the EPNS is invoiced for the costs incurred by BPNA. Income not invoiced as al the reporting date is recognised as accrued income within the financial Sthlemenis. Expenditure Liabilities are recognised as expenditure as soon as there is a legal or ¢onstru¢tive obligation committing the chariiy to ihal expendiiure, li is probable that a transfer of economic benefjls will be required in seltlemenl and the amount of the obligaiion can be measurcd reliably. Expenditure is accounted for on an accruals basis and has been classified under headings ihat aggregate all cost related to the extegory. Where costs canno¢ be directly atiribuled to particular headings they have been allocated to activities on a basis Consistent wilh ihe use of resources. Granis offered subject to conditions which have not been met at the balance sheei date are noied as a commitment but noi accrueil as expenditure. Tangible fixed assets Depreciation is provided at the followillg dDnual raics in order to write off each &lSSCt over lis estimated useful life. Planl and machinery Fixtures and fillings 25% on reducing balance 25Yo on reducing balance The tangible fixed assets of the charity are reviewed by the charity's executive director and the trustees for impoinneni on a regular basis and during the preparation of the financial siaiemenis. Stocks Stocks are valued al th¢ lower of cost and nel realisable value. after making due allowance for obsoleie and slow moving items. Taxation The charily is exempi from lax on its chariiable activTrties. Fund accounting Unrestricted funds can be used in accordance with ihe chariiable objectives at the discretion of the trustees. Restricled funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular reslricted purposes. Further explanalion of the nature and pu￿}0$e of each fund is included in the notes to the financial statements. Page 39 continued...

Brffitlsh Paedlatrie Neurology Association Noles to the Flnan¢lal Statemenls . continued for the Year Ended 31 March 2025 ACCOUNTING POLICIES - Contlnued Deblors and creditors receivable I payable within one year Debtors and creditors with no slated interest rate and receivable I payable within orje year are recorded at transactioll price. Any losses arising from impainnenl are recognised in expenditure. Foreign currencies Assels and liabiliiies in foreign currencies are iranslated into sterling ai the rares of exchange rnling at the balance sheet date. 'l-ransactions in foreign CULTen¢ies are translated into slerling al the rate of exchange ruling al the dale ol transllclion. txchangc diflcrcnccs 1￿c tdkcn inlo dccount in a￿1VIng dt the operating Tcsult. Pension eosts and other post-retirement benefits Thc ch￿ilY opcratcs a defined contribution pension Scheme. Contributions payable to thc charity £ t￿nSIOn .8cheme are charged to the Statement of Finan¢i31 Activiti&s in the perii)d to which they relate. Fin2nei21 inslruments A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instNmenls. Basic fjnancial instruments are initially recognised at the transaction price, unless the arrangement constitutes, in effect, a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debi instrument. Debi instruments are subsequently measured al amortised cost. Oiher financial instruments are initially recognised at fair value, unless payment for an asset is deferred beyond ormal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the ￿lUTe payments discounted at a market rate of interest for a similar debi instrument. Financia] asseis that are measured al cosi or amortised cost are reviewed for objeciive evidence of impairnienl at the end of each reponing date. If there is objective evidence of impairinent, an impairnient loss is recognised in profil or loss immedialely. Any reversalq of impairnient are recognised in profil or loss immediately, to the extent Ihat the reversal does not result in a carrying amount of the t'inancial assel thal exceeds what the carrying amount would have been had Ihe impainnent not previously been recognised. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCER TAINTY The preparation of the financial statements requires management lo make judgements, estimates and assumptions that affcct thc amouuls rcponcd for assets and liabilities as at the balancc 5heei dale and the amounts reported for revenues and expenses during the year. The nature of estimation rneans that actual outcomes may however differ from those original estimates. The trus*es do not deem (here io be judgements, apart frorn those otherwise disclosed in the acwunting policies or notes to the financial siatements, whlch require highlighting to the readers as a resuli of having had a Critical effeci on amounts recognised in the fmancial slaiemenls. Page 40 continued...

British Paediatric Neurology Assoeialion Notes to the Fln#ncfial Statements . continued for the Year Ended 31 March 2025 DONATIONS AND LEGACIES 2025 2024 DonalioDS Grants Membership donations Annual conference sponsorship Shon course sponsorship Trainee sponsorship UCB Sponsorship Miseellaneous income 142 209,505 10,8(X) 74,432 40.250 7,500 15,(KKI 1,386 23,660 242,718 11,2(M) 110,500 14,750 7,500 795 359 015 411.123 Grants received, included in the above, are as follows.. 2025 2024 International League Against Epilepsy (ILAE) Department for Inlernalionaj Development (DFID) via the Tropical Health and Education Trusl {THET) Pet Grant BAND & ROW Foundalions Grant Tunisia Launch LiTranova Support 57,664 114.525 54,878 156,300 s,￿0 26.540 12,316 25,1)1)O 209,505 242.718 Sponsorships received, included in the above, are as follows= Conference sponsorship Course sponsorship 2025 Toials 2024 Totals Company name Acadia Alexion Biocodex Biog¢i) Desilin Egelis Neuraxpharni UK Immedica Novartis Nutricia Orchard Proveca 6,000 7,500 6,000 7.500 39,250 7,51KI 7,500 7,500 19,750 6,000 6.000 2,000 7.500 6,000 7,500 2,000 6,(N)O 8,500 7,500 13,500 7.500 6,UOO 33,250 7,500 6,000 7.500 6,000 6,0(Kl 6,0(Kl 7,500 6,0(K) 8,SIK) 6.0 1.000 Roche Sarepta UCB Pharma Veriton 7,500 13,51K) 7,500 16.51)0 6.000 1,500 6,000 1,500 Young Epilepsy Page41 continued..

British Paedigtrie Neurology Association Notes to the Financial Statements . continued ror Ihe Year Ended 31 March 2025 DONA TIONS AND LEGACIES . continued Childrens Trnst Mackeith prize ITF Pharma Santhera Epilepsy Research Ring 20 Livanova 1,51KI 500 1,500 51K) 1,500 130 1,5 130 3,0(Kl 3,000 Total Sponsorship 128 130 40.250 168,380 125,250 INVESTMENT INCOME 2025 2024 Deposit account interest 14,794 12,388 INCOME FROM CHARITABLE ACTIVITIES Distance learning courses International short courses Annual conference Short courses Research Annual conference Short courses InierDaiional short courses Distance learning BPNSU fee income Trainee fees BPNA membership subscriptions Annual Collference ymposium sponsorship Exiernal room hire 247,678 380,843 16,151 63,155 720 313 678 380,843 63,155 16,151 720 2025 2024 Membershlp and professional support Professional support Support osts Toial activities Total activities Annual Conference Short courses International shorl courses Disiance learning BPNSU fee incorne Trainee fees 247,678 380.843 16.151 63.155 720 6.641 243.080 288.591 3,469 67.28 1 1,200 6.641 CarrAed forward 6,641 715.188 609.120 Page 42 coniinued...

Brlttsh Paedlatric Neurology Association Notes to tbe Financial Statements - continued for the Year Ended 31 March 2025 INCOME FROM CHARITABLE ACTIVITIES - eonlffinued 2025 2024 Membership and professional bupporl Professional supporl .8uppoTI costs Toldl activitiC5 Tolal activitics Brought fonvard BPNA membership sub5CriPtions Annual canference symposium sponsorship F.xtern31 mom hire 6,641 715,188 609,120 121,910 121,910 117,784 66,(KiO .200 66,000 1,350 ,200 121,910 6,641 1,200 904,298 794 254 Sponsorships received, included in the above, are as follows: Symposia sponsorship 2025 Totals 2024 Totsls Company name Biocodex Biogen Desilin GWlJa22 Pharma rrF Pharma Novartis Immedica Roche UCB Pharnia i i,o(M) 11,000 11,000 11,000 11.000 11,000 11,000 11,000 11,000 l i.O(K) 11.000 l i,O(K) 11.0 11,000 i i,{)00 11.000 11,000 11,000 Total Sponsorship 66.0￿ 66,000 66.000 Page 43 continued...

British Paediatric Neurology Association Notes to the Finanefial Statements . cont5nued for the Year Ended 31 March 2025 CHARITABLE A￿1VITIEs COSTS Grt4nt funding of activities (see nole 8) Support ¢osts (see nole 9) Direcl Costs Tolals Annual conference Short courses Disian¢¢ learning courses In*rnational short courses Research Membership and Professional supporl Support Costs Governance cosls Invitrd Reviews 193,427 213,993 17,930 21K),664 2.469 80,085 (78,571) 49,008 691 91,104 127,017 32,182 126,445 18.219 54,280 113,512 36,512 284,531 341,010 .50,112 327,109 62,354 134,365 34,94E 85,223 691 41,666 679,696 41,666 598.974 1,320,336 GRANTS PAYABLE 2025 2024 Research 41,666 The ioial granis paid io instituiions during the year was as follow5-. 2025 2024 Year 2 of 3 joini research training fellowship with Action Medical Research Year 3 of 3 joini research training fellowship with Action Medical Research 41,667 41,302 41,666 41,666 SUPPORT COSTS Infonnaiion Eechnology Human resources Fitiance Annual ¢onfer¢nce Short courses Distance leaTning courses Iniernaiional short courses Research MembershÉp and professional support Support cosis Governance costs 282 394 11)0 393 57 169 8.382 11,686 2,960 11,635 1,676 4.994 61,401 85,604 21,687 85,220 12,281 36,582 113.512 16,722 77 2,284 43,617 433,009 Page 44 continued...

Brilish Paediatrie Neurology Association Notes to the Financial Statements . continued ror the Year Ended 31 MaTeh 2025 SUPPORT COSTS - continued Governance costs Other Totals Annual conference Short courses Disiance learning courses International short courbes Research Membership and professional support Support cosis Governance cosis 19,508 27,196 6,893 27,070 3,899 11,621 ,531 2.137 542 2,127 306 914 98,888 137,870 34,931 137,249 19,776 58,918 113,512 38,335 5,314 11,818 101,501 19,375 598,974 Support costs, included in the above, are as follows: Distance learning courses International short courses Annual conference Shon courses Research Loss on sale of 18ngible fjxed a55ets Software subscriptions Computer repairs Websile hosting Websiie development Compuier upgrades Depreciation of tangible fjxed asseis Employment costs Social security Pensions Staff costs Staff iraining & wel[￿e Recruitmeni cosis Business rates Gas and elec(ric Telephone Office insurance Data protection costs Health and salely cosls Legal fees m￿ke(Ing Office repairs and renewals Photocopier Printing and stationery Indemntty insurance Credit card chargeb Bank charges 282 1.515 152 117 5,359 96 394 2,113 211 162 7,472 134 loo 535 53 41 1,893 34 393 2.103 210 162 7.439 133 57 303 30 23 1,072 19 1,143 48,271 5,989 3,971 775 2,316 79 174 89 853 32 1,594 67,301 8,350 5,535 1,079 3,229 iio 243 124 1,190 44 J.588 66.999 8,312 5,510 1,075 3,214 iio 242 123 1,185 44 229 9,655 1,198 794 155 463 16 35 18 171 17,051 2,115 1.402 273 818 28 62 31 302 35 38 2,342 228 128 245 1.349 2,506 130 50 54 3.265 317 180 342 1.883 3,493 182 13 14 827 80 46 87 477 885 46 50 54 3,250 315 179 341 ,874 3,477 181 468 45 26 49 270 501 26 Carried fonvard 78,222 1119,060 27,630 108,572 15,645 Page 45 conttDiied...

British Paedigtric Neurology AssocFatlon Notes to the Financlal Statements . eonllnued for the Year Ended 31 Mar¢h 2025 SUPPORT COSTS - ¢ontinu¢d Distance learning courses International short Courses Annual onference Short courses Research Broughi forward Bad debi expense Refuse and cleaning Computer and internet Sthff we]f￿e Copyright licence London Rent Bolton Reni Meeiing costs VAT penalty proi'ision Consuliancy Professionat fees Depreciation of tangible fixed assets Audiiors, remuneration Auditors, remuneration for non audit work Ac¢ountancy and legal fees 78,222 28 73 li I 108 155 6,340 2,558 341 1,153 214 127 109.060 39 ioi 154 150 215 8,841 3,566 476 1,606 298 175 27,630 io 26 39 38 55 2,240 903 121 407 76 108,572 38 loo 153 149 214 8,801 3.549 474 1,599 297 174 15.645 14 22 22 31 1,268 511 68 230 43 25 143 199 51 198 29 85 1.446 121 2.016 31 511 120 17 289 91,1(M 127 017 126,445 18,219 2025 2024 Membership professional support Support cosls Governance Costs Total activiiies Total activities Loss on sale of tangible rixed asseis Sofiware subscriptions Computer repairs Websiie hosting Website deiTelopment Computer upgrades Depreciation of tangible fixed assets Employment costs Social security Pensions Staff Costs Staff training & We]f￿e Recruitment costs Business rates Gas and electric Telephone Office insurance 169 903 90 69 3,193 57 77 413 41 32 1,460 26 1,472 7,885 787 606 27,888 499 652 9,446 1,486 540 6.625 284 682 28,761 3,568 2,365 461 1,380 47 104 53 509 19 312 13,146 1,631 1,081 211 631 22 48 24 233 5,952 364,696 31,163 20,658 4,029 12,051 412 6,931 353,618 29,887 21,053 2,269 13,237 2,017 195 245 4,079 2,290 113.512 462 4,443 165 Carried forward 42,430 113.512 19,397 484,076 454,854 Page 46 continued...

Bri¢ish Paediatric Neurology Association Notes to the Financial Statements . continued for the Year Ended 31 March 2025 SUPPORT COSTS - continued 2025 2024 Membership and professional support Support Losts Governance costs Total activities Total aeiivitie5 Brought fonvard Data protection costs Health and safely Costs Legal fees Marketing Office repairs and renewals Photocopier Printing and stationery Indemnity insurance Credit Card Charges Bank charges Bad debi expense Refu.se and cleaning Computer and internet Siaff welfare Copyright licence London Rent Bolion Renl Meeting costs VAT penalts, provisio Consuliancy Professional fees Depreciation of tangible fJAed assets Auditors, remuneration AudilOfS' remuneration for non audit WOTk Accountancy and legal fees 42,430 113,512 19,397 484,076 35 186 202 12,185 1,182 671 1,277 7,026 13,037 679 143 377 575 560 804 32,995 13,307 1.776 5,995 1,113 654 454,854 239 21 23 1.395 135 77 146 805 1,493 78 16 43 66 io 4,254 16,700 608 127 952 638 62 35 67 368 682 36 8.964 1.027 (66) 48 20 30 29 42 1.727 696 93 314 58 34 5.055 730 37.512 10,055 2.181 92 3,778 1,524 203 686 127 75 9,807 85 39 744 150 10,800 52 862 24 2,794 450 9,925 5,167 54.280 113.512 36,215 598,974 570,073 io. TRUSTEES, REMUNERA TION AND BENEFITS There were no INsiees' remuneration or other benefits for Ihe year ended 31 March 2025 nor for the Ye￿ ended 31 March 2024. Page 47 continued...

British Paediatric Neurology A550ciatio Note5 to the Financial Statements . continued for the Year Ended 31 March 2025 io. TRUSTEES, REMUNEILITION AND BENEFITS - continued Trustees, expenses Within ihe expenses noied above are expenses paid lo ihe following irnslees in respect of direct charitable iILlivily costs i.c. trdvcl cxpcnscs tcaching al UK andlor Intcrnational courscs, undcrtdkcn un bchalf ot" the Lharity in the year: 2025 2024 Prof M Kirkpatrick Dr A Parker Dr A McLellan Dr M Griffiths Dr S Moi'dekar Dr D RaJn Dr S Amin Dr M Prasad Dr Lumsden Dr M Chitre 7,548 14,153 564 4,425 636 658 7U9 1.62.3 720 3,503 1,636 1.693 1,8(N) 1,447 459 2,428 149 20,514 23,637 During the year, in addilion lo Ihe above, amounts loialling £5,227 (2024 £4,434) relaled io executive meeiing expenses that were paid on behalf of all ￿U5[eeS. ii. STAFF COSTS 2025 2024 Wagcs and salaries Social .8ecurity costs Pension schemes 363,043 356,738 29,887 21,053 20,658 Total 408,257 407,607 The average monihly number of employees during the year waq as fDIIDws'. 2025 2024 Managcment Supp()rt staff li li The number of employees receiving gTOSS remuneration, inclusive of the value of benefits-in-kind, greater than £60,000 per dnnum and to whom retirement benefits are accruing under defined contribuiion pension schemes were.. 2025 2024 £60,￿o- £70,IKK) Total employees Page 48 continued...

Brfitlsh PaediatrSe Neurolo￿ Association Notes to the Financial Statements . continued for the Year Ended 31 March 2025 STAFF COSTS - eontlnued Total remuneration paid to key management personnel during the financial year included wages and salaries amounting to £184,746 (2024 - £161,792) and contributions to defined contribution pension schemes of £10,285 (2024- £10,055}. 12. TANGIBLE FIXED ASSETS Fixiures and riltings Plant and machinery Totals COST At l April 2024 Additions Disposals 45,359 4.723 3,057 2.868 1.490 48.41fi 7,591 At 31 March 2025 41,261 45,696 DEPRECIATION At l April 2024 Charge for year Eliminated on disposal 24,566 5,952 7,110) 2,607 744 27,173 6,696 Ai 31 March 2025 23,408 25,613 NET BOOK VALUE At 31 March 2025 17,853 2.230 20.083 At 31 March 2024 20.793 450 21.243 13. STOCKS 2025 2024 Stocks 939 9,023 14. DEB TORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 2025 2024 Trade debtors Other debiors Prepayments and accrned income 41,125 13,701 55,214 21,0￿ 43.543 110,040 65,203 Page 49 continued..-

British Paedlatrlc Neurology Assoclation Notes to the Financial Slatements . continued for the Year Ended JI March 2025 15. CREDITORS: AMOUNTS FALLINC DUE WITHIN ONE YEAR 2025 2024 Trade Creditors Social security and other taxes 59,830 14,002 VAT Other creditors Deferred income Accrued expenses 2,121 2,613 88,670 32.171 154 84,301 26,966 205,890 185,253 The deferred income balance above include5 income relating to training courses amounting to £88.540 {2024 - £84,171) and membership subscriptions received in advance amounting to £130 (2024- £130). 16. LEASING AGREEMENTS Minimum lease payments under non-cancellable operating leases fall due as follows: 2025 2024 Within one year Between one and five years 6.807 16,534 3,578 20,112 Dwing the year the charity incuffed expenditure under eancellable and non-cancellable operating lease agreements relating to offjce ￿ntaI amounting to £46,302 (2024- £47,567). 17. PROVISIONS FOR LIABILITIES 2025 2024 ovisions 5,995 Page 50 continued...

British Paediatri¢ Neurology Assocfiallon Notes to the Financial Statements - continued for the Year Ended 31 March 2025 18. MOVEMENT IN FUNDS Net rnovement in funds Transfers between funds Ai 3113125 At 114124 Unrestricled fund5 General fund Contingency fund Research training fellowship fund Fetal Neurology course development Kenya Fellowship Travel Fund Disiance Learntng Development Fund Impac( & Evaluaiion consultancy International face to face Imunch Websiie Upgrade CHaT course update NeoNaie course update 163,430 250.000 96,679 10,448 1,000 55,145 49,0 169,721 65.243 398,394 250,(K)O (41.667) (55,012) 10,448 (1,000) {6,060) (9,780) 49.085 39,220 100.(Kio (20.963) 7,200 79,037 (7,2(Kl) 785,702 100,482 886,184 Restricted funds ILAE grant fund 198 (135,142) (7,767) 198 14,119 3,703 THET grant fund Zambia Launch Internation￿ faculty education & fellow travel bursary fund 149,261 11,470 17,320 17,320 178,051 142,711 35,340 TOTAL VUNDS 963 753 42,229} 921,524 Page51 continued...

British Paediatric Neurology Associatlon Notes lo the Finaneial ,Stalements . continued for the Year Ended 31 March 2025 18. MOVEMENT IN FUNDS - contfinlled Nel movement in funds, included in the above as follows: Incoming resources Resources expended Movement in funds Unrestricted funds General fund Research training fellowship fund Kenya Fellowship Travel Fund Disiance Learning Development Fund Impact & Evaluaiion consultancy CHaT course update NeoNate course update Dlstance Learning THET Grant LIvk￿0Va Iniernaiional Grani 1,068,603 (898,882) (41,667) (1,000) (6,060} {9,780) {7,200) (3,532) (9,072) (25,01)0) 169,721 {41,667) { 1,000) (6.060) (9,780) (7,21Xl) (3.532) 9,072 25.000 1,102,674 (1,002,192) 59,977 Restricted funds ILAE grant fund 69.980 105,453 (69,782) (240,595) 198 {135,142} THET grant fund Zambia Launch 175,433 13 18,144) 142,711 TOTAL FUNDS 1.278,107 1.32(1,336 42,229) Page 52 continued...

British Paediatric Neurology Association Notes to the Financial Statements . continued for the Year Ended 31 March 2025 18. MOVEMENT IN FUNDS - continued Comparatives for movement in funds Nel movement in fund8 Transfers between funds At 3113124 At 114123 UtJres¢ri¢ted funds Gen¢ral fund Conlingency fund R&sear¢h training f¢llowship fund Fetal Neurology course development International Faculty Education Fund Kenya Felloivship Travel Fund Fellow Travel Bursary Fund Distance Learning Development Fund PET Update Course DeTrelopment 348,574 180,(X)O 179.648 10.730 10.195 ,000 7,125 67.825 15,462 (200,606) 70,0(X) 163.430 250,0(Y) 96,679 10.448 (82,969) (282) (10,195) (7.125) (12.6801 55.145 25,143 17,600 50,(KKI 21,722 (18,418) (7.858) (1,000) (1,119) (9,823) (6,725) (9.742) PET Hot Topics course development Impact & Evaluation consultancy Movement Disorders course development PET 213 Intemaiional Update International face 10 face launch Websile Upgrade 49,000 (20.603) 9.823 60,000 iOO.O(K) 60,000 100,000 919,562 (118,687) {15,173) 785,702 Restrieted funds THET grani fund Colombia Launch Zambia Launch International faculty education & fellow travel bursary fijnd 149,261 (10,929) 11,470 149,261 13,076 {2,147) 11,470 17,320 17,320 13.076 149,802 15,173 178 051 TOTAL FUNDS 932,638 31,115 963.753 Page 53 continued...

Brltish Paediatrie Neurology Assoelatlon Notes to the Flnancial Statements . continued for the Year Ended 31 March 2025 18. MOVEMENT IN FUNDS - contlnued Comparative nel movement in funds, included in the above are as follows.. Incoming resources Resources expended Movement in funds Unrestricted funds General fund Research traillinE fellowship ￿nd Fetal Neurology coursc dcvclopmenl Distance Learning Development Fund PET Update Course Development PET Hot T()pics course developmcnl Impact & F.valualion consllltancy Movement Disorders course development PFf 213 Jnternational Update 956,643 (941.181) (82,969) (282) (12.680) (18.418) {7,858) (1,000) {1,119) 15.462 (82,969) (282) (12.680} (18.418) (7,858) (I,(XMI) (1,119} 956,643 (1.075.330) (118.687) Restricted funds ILAE grant fund 54,877 159.504 {3,204) 49,945 (54.877) (10,243) (7,725) (38,475) THET grant fund Colombia Launch Zambia Launch 149.261 (10,929) 11,470 261,122 111.320 149,802 TOTAL FUNDS 1,217.765 {1,186,650) 31,115 Contin enc . fund The contingcncy fund is held io support the staffing cosi of running the BPNA SecretariAt for a period of approximatcly six months {2024 - six monihs) should there be any conungency that might ledid io a significant reduction in BPNA operation21 activities, Ihis cquatcs lo £250,000 (2024 - £250,000). RcscarLh Trainin Fellowshi Fund The Research Training Fellowship funds traincc cliniLiaIis lo complete a research degrcc (cg PhD) in thc ficld of cIiDical neurology andlor neuroscience, includin¥ ueurodisabilily and neurodevelopmeni. Fellowship appliLanlS are pre-doctoral trainee clinician5 who either already hold a UK or Irish speciali81 iraining post in Paediatric Neurology or are pldnning to apply for a specialist training post in Paethatric Neurology or Neurodi8ability after cninpletion of thcii PhD. Both the proposed application and fellowship applicani must meet the BPNA charitable aims. Income to this fund is from members, donations and the income fro￿ sponsored symposia at the BPNA annual conference. Since 2015, the BPNA has parlnere4J wilh Aclion Medical Research lo fund a joint Research Training Fellowship award. Applications for ihis joint award are considered in open competition through the A¢lion Medical ReseaTch peer review system. Pagc 54 continued...

Britlsh Paedlatric Neurology Assocl8tion Notes to the Flnan¢i81 Statements - continued for the Year Ended 31 March 2025 18. MOVEMENT IN FUIIDS - continued Felal Neurolo. Course Develo ment The Fetsl Neurology course developmeni fuDd is a designated fund set up by the Trustees to fund development of a course designed to improve training for anyone involved in caring and counselling a family whose fetus has neurological abnorniality. This funding is provided from iransfers from Ihe general fund. Ken 'a Fellowshi Travel Fund In 2019, the BPNA and Kenyan Paediatrlc Association established a fellowship for UK paediatric neurologists to go io work in Kenya for a short period. The KPA will pay Ihe UK clinician's salary. This fund is io cover ihe cost of their rewrn travel expenses. Di.stancc LcaTlliTJ Dcyclo cnt Fund The distance leArning development fund is a designated fund set up by the trustee5 in ordcT lo prescrvc the anticipalcd Icvcl ol funding inLurrcd IOT disidnce leaming course development in the foreseeable fll￿re. This fundinu is PTDvidcd fiom ITanslcrs Iiom the gener￿ fund. ct & Evaluaiion Officer The BPNA has bccn running courses since 2￿_S. This money is to fund an Impact and Evaluation OfFicer to report on the full irnpact of BPNA cou15es. Inlemational face to face launch This fund undcrwTltes thc cost of inlcn)aLional PET launches. enabling organisational arrangejnents to be made while external funding is sought to eover the costs of the launches. Websitc rade This ￿nd has been put aside foT the update of the BPNA website. There will be consultancy who will research inEO the BPNA website's needs and also a brand redesign. CHaT course u ate The CHaT course was last updated in 2018. This money will fund the bringing together of a development leam to update the CHaT Course materials to refle¢1 feedback, updates in rese4wch and guidance. NeoNate course u ate The NeoNATE course was last updated in 2018. This money w'ill fund the bringing together of a development team to update ihe NeoNATE course mdlerials lo reflect feedback, updates in research and guidan¢e. Inlernalional Lea ueA ainsi E ile s ILAE ant fijnd The BPNA and ILAE share a commitment to improving care for children with epilepsy. In 2005, the BPNA developed Paediatrie Epilepsy Training {PET) courses to ￿ain healthcare workers to belter diagnose and ireal children with seizures. PETI is now aitended by almost every paediatrician in the UK and the courses hdve also been launchcd ovcr&L115. SLlling il gold blandaTd for epilepsy care around the world. Outside of the UK, the prograrnme cU￿C￿tIY tuns in: Br￿1, Ghan4 Indiu, Keny& Myanrnar. New Zea]and, South Africa, Sudan, Tanzania and Uganda. PET aligns wi(h IhL ILAE'S EduLulion Council's aim to teach competency in the diagnosis and clinical maDagemeni of epilepsy, with a focus on non-speciaIi8L8 i.e. paediatTiCidns. li furlljs part of the porilolio ol cducational activiiies that the Il.AF. aims io develop. It also 5UPPOrts Goal 2 of thc ILAE'S Stratcgy 2030= Suppoil healih professionals worldwide to enhance tbeir knowledge and skills in the preveniion. diagnosis, treatment and care of epilepsy. The BPNA and the ILAE. first signed a partnership agreement in 2018, committing to build on the success of the Paediatric Epilepsy Training course5 developed by Ihe BPNA. The ILAE has agreed to cover 40% of Staff costs in the BPNA'S International Education team (3 staff mernbers) from April 2022 to March 2026. This equ&tes to a total of $278,844 over that ume. Page 55 continued...

Brftlsh Paedlatric Neurology Association Notes to the Finaneial Statements . continued for the Year Ended 31 March 2025 18. MOVEMENT FUNDS - tontthnued THET ni fund The BPNA was awarded a grant by Global Health Partnerships (forn)erly Tropical Health and Education Trust) to lake PET to rural regions of Ghana and Kenya. Zambia launch PET was launched in Zambia in 2023, with thndillg from generous donors. These funds represeni the underspend against the origindl budget and we now have permission to use them for other PET acitviiies in Sub-S&haran Africa. International Facult Educdtion Fund To enable Low and middle income country (LMIC) BPNA course faculty to benefit from BPNA cduLaliDn by funding registration fccs. Thc airn is to 5uppuri faLuliy to pay lor courses that they would otheTWiSC bc unable to afford. BPNA Education includes= facc-to-facc couiscs and conlerences held in the UK, virtua] courses or onferences and enrolment on distance learning unils. It does not fund travel or accornmudalion. Fellow travel bursar fund BUrs￿Y fund for UK trainees and fellows. Acute Neurolo The Acule Neurology course development fund is a designated fund sel up by the Trustees to fund devclopm¢nl of a new l-day course dcbigncd to Icach pacdiatTiC emergency medicine staff, paediatri¢ian5 and trainccs to recognise acute neurological conditions and manage appropriately. This funding is provided from transfers from the general fund. Priorit Settin The BPNA commilted £50,000 to undertaking a research priority setting project IPSP) in paediatiic neurology, facilila(ed by the James Lind Alliance. This p#rtnership aims to shape future research on pa¢dialri neurological conditions by bringing together patients, their pl￿entS and carers and health care professionals to identify and pnoritise unanswered research questions around treatments, therapies or procedures. outcome of the project will be a lisl of the lop 10 jointly agreed research priorities. These priorities will then be promoted to research funding organisations to infiuence future research. The PSP commenced October 2019, aiming to compleie September 2020. however due to Covid-19, the project was extended 10 31 March 2022. During 2020-21, a survey was promoted to clini¢ians, paiienis and carers to complete online. The responses were analysed filtered, and a second survey was sent out in 2021-22. li asked them to identify their lop research priorities in paediatric neurology from a list of 44 questions. These responses were analysed and filtered dnd produced a lop 26 final list of unanswered questions. The final prioritisation workshop was held with various stakeholder groups on 30 March 2022 in London, with Ihe objectives to finalisc top 10 rCsc￿ch qucslions from the final 26. The top 10 and the othcr 16 that did not mukc thc lop 10 were published in a final sun]mary documenl in November 2022 as 'Top Ten UK research priorilies for interventinn.s in childhood neurological disvrdcrs. and was well reLelVCd. The aim now would be looking inlo how some of these questions can be researched ￿4th the support of the BPNA interested stakeholders. A Pre-confcicncc Tiainccs, researLh nelwork meeling happened at the BPNA2023 Conference with discussion about the AMR Fellowship and Pri()rity Setting Projccl rcsults, Lh ment PETI was last updated in January 2018. This money will fund the bringing together of an inten)alional development team to updat¢ PETI course materials to reflect feedback, updates in research and guidance. Page 56 continued...

British Paedi&tric Neurolo%y Association Notes to the Financi21 Statements . continued ror the Year Ended 31 March 2025 18. MOVEMENT IN FUNDS - eonllnued PET Hot To ics Course develo ment To fund development of a new course designed for those who attended PET2 and 3 more than 3-years ago. Movemeni Disorders course develo eni MOVED MUVED is a 2-day LuufsL bel￿g dcveloped by Consultant Paediatric Neurologi8ts and Paediatricians in Neurodisability. It will run as a Siand alone course, bui will develop (hemes from the Approaching Children's Tone (ACT) course. This course aims to cover a broad .8pectrum of Tnovemcnt disorders that are seen in children and will place emphasis on description, diagnosis and initial management of these condiuons. Columbia Launch Fund In patlnerbhip with the Universily of Anlioquia and ASCONJ. Ihe Colombian Child Neurology Society, BPNA launched PETI in Colornbia in August 2022. The Buisl Foundarion: ILAE South America Region and Jazz Pharn]aceuticals have coniribuied to the Colun]bia Launch Fund. LivaNova Fund To support ihe international PET programme in 2025. Transfers between funds The transfer8 beEween designaied funds and the genera] fund have been undertaken in OTder to ensure a suilable level of reserves has been designated as at the reporting dale for the pu￿0$¢8 of the funds listed. During ihc Yc￿, thcic were no transfeis lo or fiom restricted funds (2024 - a transfer frotn the Colombia Launch re5tricied lund to the General fund of £2.147). 19. RELATED PARTY DISCLOSURES Thore were no related party transactions for the year ended 31 March 2025, nor for the year ended 11 March 2024. 20. ULTIMATE CONTROLLING PARTY The irnstees consider (here noi io be one ultimate controlling party of the British Pacdiairic Neurology Asso¢ialAon in the current or prior year. Page 57